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ABSTRACT 
 
Macrophages are the most abundant immune cells at the maternal-foetal interface of 
term placentas. They play a role in regulating pregnancy, promoting immunological 
tolerance, and maintaining a homeostatic environment crucial for foetal development. 
Numerous studies have reported the dysregulation of maternal uterine-derived 
macrophages, the decidual macrophages and the foetal placental-derived 
macrophages, the Hofbauer Cells (HCs) in pregnancies complicated by maternal viral 
infections. The immune mechanisms associated with the high prevalence of adverse 
birth outcomes amongst HIV-1 infected women on combination antiretroviral therapy 
(ART) are not well characterized. In this Ph.D. dissertation, the impact of HIV-1 
infection and the duration of ART exposure on the phenotype and function of decidual 
macrophages and HCs was studied. Birth outcomes and placenta pathologies of HIV-
infected women categorized into two groups, 1). HIV-1 infected pregnant women who 
initiated ART during pregnancy (Initiating ART n=16); and 2). HIV-1 infected women 
who initiated ART before pregnancy (Stable on ART n=14) were compared. 
Immunohistochemical and immunofluorescence staining of formalin-fixed placental 
tissues from the two groups was performed to compare the expression of macrophage 
markers associated with inflammation (M1) and immune regulation (M2). Lastly, the 
Human Protein Atlas database was used to identify novel markers of decidual 
macrophages and HCs and their potential biomarkers of HIV-1 infection. 
 
The expression of various M1 and M2-specific macrophage markers significantly 
varied between membranes of the maternal-foetal interface within the initiating and 
stable group. The duration of ART exposure had no effect on the expression of typical 
M1 and M2 macrophage markers on decidual macrophages and HCs of HIV-1 infected 
women who initiated a similar ART regimen before pregnancy and during pregnancy. 
The macrophage populations in the maternal-foetal interface co-expressed markers 
associated with M1 and M2 macrophage polarisation, suggesting functional plasticity 
of these cells. Human Coagulation Factor XIIIa1 (FXIIIa1) and Insulin-like growth 
factor 2 (IGF2) were identified as potential novel markers of HCs and decidual 
macrophages respectively, however, further validation is required. There is a paucity 
of data on the characteristics of decidual macrophages and Hofbauer cells in both 
normal and complicated pregnancies. Data presented in this dissertation suggests the 
  
possibility that HIV-infection and / the duration of ART exposure may not play an active 
role in dysregulating immune mechanisms associated with macrophages at the 
maternal-foetal interface. However, further characterization of these cells in placentas 
exposed to different ART regimens is required using the novel markers discovered in 
this Ph.D. 
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1. Review of the literature 
 
1.1. Global prevalence of HIV infection 
 
Human Immunodeficiency Virus-1 (HIV-1) is one of the greatest burdens to human 
health globally. It has been implicated in more than 35 million deaths worldwide over 
the past 30 years (Hemelaar, 2013). According to the UNAIDS/WHO-2018 fact sheet,  
in the year 2017, 36.9 million (31.1 million – 43.9 million) people were living with HIV 
globally and approximately 59% of these people were on antiretroviral therapy (ART) 
(UNAIDS, 2017b). They also reported that 80% (61 - 95%) of pregnant women living 
with HIV had access to antiretroviral therapy. Despite this, women of child-bearing age 
are most affected by the HIV pandemic, especially in developing countries. In the 
African continent, an estimated 1 in 25 adults is living with HIV, that makes up 
approximately two-thirds of the world’s population of people living with HIV (UNAIDS, 
2017b). Global trends suggest that HIV infections are still on the rise, however, AIDS-
related deaths have decreased significantly and this is mainly attributed to widespread 
use of antiretroviral treatment. Figure 1.1 below shows recent global trends in HIV-1 
prevalence for the year 2017 (World Health Organization (WHO), 2017). 
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Figure 1.1: Global prevalence of HIV among adults, aged 15-49 in the year 2017 
(WHO, 2017).  
1.2. HIV infections in South Africa 
 
An estimated 7.1 million South Africans were living with HIV in 2016. HIV prevalence 
is at 18.9% among the general population, making it the highest in the world (UNAIDS, 
2017b). Despite having the world’s largest ART programme, the HIV epidemic 
continues to have devastating social, economic and health effects on South Africans. 
Women and children are the most affected population. The prevalence of HIV 
infections among pregnant women increased continuously from the year 1990 to 2005, 
but slowly decreased when the country increased its ART roll-out programmes 
between 2005 and 2010 (Figure 1.2). The HIV pandemic is more than just a health 
problem. From 2015, the South African government invested more than $1.34 billion 
in its HIV prevention programmes (UNAIDS, 2017a). However, the HIV pandemic 
continues to have negative effects on the country’s social and economic development 
(Dixon et al., 2002).  
 
Increased mortality and morbidity due to HIV infection has not only affected the 
country’s economy, it has also weakened the family system leading to an increased 
number of child-headed households and homelessness (Taraphdar et al., 2011). It is 
estimated that more than 2 million South African children are orphaned due to the HIV 
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pandemic (UNICEF, 2016). Orphaned children are at higher risk of contracting HIV 
because of economic and social insecurities. They often become sexually active at a 
younger age than other children and are at a risk of being forced into sex in exchange 
for financial support ((SANAC), 2017). Primitive cultural and sexual practices make 
women of childbearing age much more vulnerable to HIV infection than men. Although 
the number of Acquired Immunodeficiency syndrome (AIDS)-related deaths has 
decreased by 29% since the year 2010, it was reported that more than 100 000 people 
died from AIDS-related deaths in the year 2016 alone (UNAIDS, 2017a). The country’s 
economy has plummeted due to loss of skilled labour and lack of investor confidence. 
The country’s weak economy has led to high levels of youth unemployment and 
subsequent social problems such as drug abuse and crime. A weakened family 
system resulting from AIDS-related deaths and lack of financial support can also be 
associated with high levels of prostitution which further increases the risk of HIV-
infection amongst women and the youth. 
 
 
Figure 1.2: HIV prevalence among pregnant women in South Africa (Adapted from 
www.avert.org , accessed November 2018). 
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1.3. HIV/AIDS Treatment: Antiretroviral therapy 
 
Management of HIV infections has improved in recent years; this is attributed to 
increased access to combination antiretroviral therapy (cART). Life-time dependency 
on ART due to persistent HIV viral reservoirs presents major health and economic 
challenges. In the past two decades, the use of Antiretroviral therapy (ART) by 
pregnant women living with HIV has had remarkable results on the epidemic of HIV in 
infants. There was a drastic 80% decrease in new infant infections, a decrease from 
590 000 in 1998 to 120 000 in 2016 (UNAIDS, 1998, UNAIDS, 2017b). Despite this, 
women of reproductive age (15-24 years) are highly susceptible to HIV infections. It 
was reported that 51% of people living with HIV are female (UNAIDS, 2017b). 
Antiretroviral drug regimen used to for the prevention of mother-to-child transmission 
of HIV has evolved from zidovudine single-drug prophylaxis used in 1994 to the current 
triple-drug regimens (Connor et al., 1994, Fowler et al., 2017).  
 
The hypothesis is that ART controls HIV viral replication, resulting in low or 
undetectable viraemia that drastically decreases the risk of HIV transmission. 
However, the mechanisms of how these drugs prevent HIV vertical transmission is not 
fully understood. Since 2009, the number of people accessing ART in South Africa 
has increased exponentially (Figure 1.3). However, there is very little information on 
the effect of prolonged ART exposure on the immune system of people living with HIV, 
especially women of childbearing age. The effect of different ART regimens 
administered during pregnancy on birth outcomes is not well understood. A recent 
study reported that ART drug, dolutegravir, causes neural tube birth defects in infants 
born to HIV-infected mothers that received treatment during pregnancy (Zash et al., 
2018). There is a need for pharmacovigilance to assess immune dysregulation caused 
by ART exposure during pregnancy and in infants exposed to ART while in utero.  
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Figure 1.3: Exponential increase in the number of people receiving antiretroviral 
therapy in South Africa. (Adapted from www.avert.org, accessed in November 2018). 
 
1.4. Classification and geographical distribution of HIV 
 
The virus responsible for causing AIDS was first isolated from severe 
immunocompromised patients and classified to the lentivirus family of retroviruses 
(Barresinoussi et al., 1983, Levy et al., 1984, Popovic et al., 1984) and termed Human 
Immunodeficiency Virus (HIV).  The virus originated from Simian Immunodeficiency 
Viruses (SIVs) of primates and it was classified into HIV-1 and HIV-2 (Galea and 
Chermann, 1998, Gallo and Montagnier, 2003, Hahn et al., 2000, Sharp and Hahn, 
2010, Sharp and Hahn, 2011). HIV-1 was derived from the SIV of chimpanzees 
(SIVcpz) while HIV-2 came from the SIV of sooty mangabey monkeys (SIVmm) 
(BarreSinoussi, 1996, Gallo and Montagnier, 2003). The SIVs did not cause 
immunodeficiency in their native host. However, both HIV-1 and HIV-2 are tropic for 
CD4+ lymphocytes and cells of the mononuclear phagocyte system, they also have 
similar genetic structures and open reading frames but differ slightly as their nucleic 
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acid sequences are 40% homologous (Dorman and Lever, 2000, L'Hernault et al., 
2012). 
 
There are numerous clades of HIV-1. The subtypes of HIV-1 were phylogenetically 
classified based on the 20-50% difference in their envelope (env) nucleotide 
sequences (Spira et al., 2003, Starcich et al., 1987). HIV-1 is grouped into major (M), 
new (N) and outlier (O) groups; these may also represent three episodes of zoonotic 
transmission from chimpanzees. Groups M and O Env proteins differ by 30-50% while 
Group N is phylogenetically equidistant from both groups M and O (Hemelaar, 2013). 
Group M HIV subtypes are mainly responsible for the pandemic and they are divided 
into subtypes A-K. The HIV-1 subtypes of Group M have an inter-subtype variation of 
20-30% while intra-subtype variation is between 10-15% (Gao et al., 1998). Due to 
high diversity in HIV-1, diagnostic testing, ART regimen and pathogenesis needs to 
be carefully monitored as these may be subtype-specific. Geographical distribution 
(Figure 1.4) of patients infected with different subtypes of HIV-1 is heterogeneous 
(Takebe et al., 2004). The remarkable genetic diversity of viral subtypes in different 
regions is due to high mismatch error rate of the HIV reverse transcriptase (RT) 
enzyme coupled with the absence of exonuclease proof-reading activity (Sierra et al., 
2005).  
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Figure 1.4: Geographical distribution of HIV-1, Group M subtypes (2016). (Adapted 
from WHO-UNAIDS HIV Vaccine Initiative). 
 
The most predominant subtype in Southern and South-Eastern African countries such 
as South Africa, Lesotho, Swaziland, Namibia, Botswana, Zimbabwe, Zambia, and 
Mozambique is subtype C (Janssens et al., 1997, Papathanasopoulos et al., 2003). 
This is also the main subtype found in South-East Asian countries like Nepal and India. 
Subtype B is found mostly in Australia, Europe and the Americas. Increased migration 
and globalization has introduced new recombinant subtypes. Reports suggests that 
40% of new HIV infections in Europe were non B-African and Asian variants (Spira et 
al., 2003, Cohen et al., 2008). Subtypes A and A/G recombinants are found mainly in 
West and central Africa (Papathanasopoulos et al., 2003) while Subtype D is the most 
predominant subtype in East and central Africa (Janssens et al., 1997). Subtype E has 
been detected in countries like Thailand, the Philippines, China and central Africa as 
an A/E mosaic (Paladin et al., 1998). Subtype F was detected in HIV-infected people 
in Central Africa (Triques et al., 1999), South America and Eastern Europe. Subtype 
G and A/G recombinant viruses were detected in patients from Western and Eastern 
Africa (Papathanasopoulos et al., 2003). Subtypes H, J and K were detected in 
patients from central Africa and Central America (Triques et al., 1999). However, it is 
important to note that due to vast changes in global migration in recent years, 
geographical distribution of HIV-1, group M subtypes may differ significantly in 2019 
and this may increase the prevalence of recombinant subtypes.  
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1.5. HIV-1 Pathogenesis 
 
1.5.1. The structure and replication cycle of HIV-1 
 
Retroviruses have an RNA genome which consists of two identical 9.2 kb single-
stranded RNA molecules (Sierra et al., 2005). The HIV virion is spherical in shape with 
a diameter of about 100 – 120nm (Sierra et al., 2005). Each virion consists of a lipid 
bilayer membrane that surrounds the cone-shaped nucleocapsid that houses the 
genomic RNA molecules, Vpu, Vif, Vpr, Nef; and the viral enzymes: protease, reverse 
transcriptase and integrase and cellular factors (Figure 1.5). It has about 72 spikes of 
the viral Env glycoproteins and the principal structural proteins forming the core are in 
the virion matrix (MA or p17), capsid and nucleocapsid (Gelderblom et al., 1987).  
 
 
Figure 1.5: A schematic diagram of the structure of HIV-1. (Created with Bio-render) 
 
The global HIV-1 pandemic over the years has indicated that the virus is able to evade 
innate, adaptive and intrinsic immunity to establish an infection (Emerman and Malim, 
1998, Bieniasz, 2004). However, there are various viral and host factors that are major 
determinants of the outcome of HIV-1 infection and the rate of disease progression, 
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these factors vary between individuals (Naif, 2013). The virus gains entry into CD4+ T 
lymphocytes by attaching its gp120 envelope proteins to the CD4 receptor, this marks 
the first step in the replicative cycle of HIV. The virus binds further to co-receptor, C-
C chemokine receptor 5 (CCR5) or C-X-C chemokine receptor 4 (CXCR4) resulting in 
the fusion of the viral envelope and the cellular membrane. This is then followed by 
the release of viral nucleocapsid into the cytoplasm (Dragic et al., 1996). The enzyme 
reverse transcriptase facilitates the reverse transcription of viral RNA into double-
stranded proviral DNA that migrates to the nucleus where integrase allows viral DNA 
to become integrated into the host chromosome as pro-viral DNA. RNA polymerase II 
transcribes the proviral DNA into mRNAs which are translated by cellular polysomes 
into viral proteins and genomic DNA; these are then transported to the cellular 
membrane and assembled. A fully-formed virion is then reproduced after processing 
of the polypeptide precursors (Dragic et al., 1996). Figure 1.6 shows the HIV 
replication cycle, starting with viral fusion at the surface of the host cell to the formation 
of a newly synthesized polyprotein creating a mature infectious virus. 
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Figure 1.6: HIV replication cycle. (https://www.niaid.nih.gov/diseases-conditions/hiv-
replication-cycle , accessed November 2018). 
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1.5.2. The role of macrophages in the acquisition of HIV-1 
 
HIV is transmitted from one infected person to another through direct contact of body 
fluids such as blood, semen, vaginal fluids and breast milk. Sexual intercourse is a 
predominant mode of HIV-1 transmission in humans (Royce, 1997). During this mode 
of transmission, HIV-1 crosses the genital mucosal barrier through small mucosal 
lesions and epithelial abrasion that may occur during sexual intercourse or because 
of other sexually transmitted infections. The first immune cell that HIV encounters in 
the epithelium are macrophages, dendritic cells and CD4+ memory T cells monitoring 
the mucosal surface (Shen et al., 2011). HIV targets immune cells that express the 
CD4 receptor at these sites (Wilen et al., 2012). It gains entry into these immune cells 
by attaching itself unto the CD4+ receptor on the cell surface, upon entry, viral-cell 
fusion occurs. Viral fusion triggers a number of intracellular mechanisms that regulate 
expression of viral regulatory and accessory genes, that subsequently leads to a 
productive or latent infection (Levy, 1993). Using the macaque-simian 
immunodeficiency virus as a model for vaginal acquisition of HIV, Stieh and colleagues 
reported that the Th17 lineage CCR6 CD4+ T cells are preferentially infected during 
vaginal infection (Stieh et al., 2016). A number of studies have demonstrated how 
mucosal infection with a variety of sexually-transmitted infections plays a role in the 
transmission and pathogenesis of HIV-1 (Dutta et al., 2017, Kolodkin-Gal et al., 2013, 
Schust et al., 2012, Tugizov, 2016). 
 
HIV is also able to gain entry into cells of the myeloid cell lineage such as monocytes, 
macrophages and dendritic cell (DCs) by utilizing the expression of CCR5 or CXCR4. 
These receptors are widely expressed by DCs, monocytes, macrophages and 
microglia of the central nervous system (Jazin et al., 1997, Moepps et al., 1997, Torres 
et al., 2001, Zhu et al., 2012, Wei et al., 2018, Creery et al., 2006). HIV is able to solely 
utilize CCR5 or CXCR4 during cell infection (Wilen et al., 2012, Venuti et al., 2017, 
Zhou et al., 2001). In vivo and in vitro studies demonstrated that both monocytes and 
macrophages can be infected with HIV-1 (Zhu et al., 2002, Crowe et al., 1987, Kalter 
et al., 1991), with macrophages being more susceptible (Iordanskiy et al., 2013). 
Monocytes are less susceptible to HIV-1 infection, but become more susceptible 
during their differentiation into macrophages (Rich et al., 1992, Sonza et al., 1996). 
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Although they express low levels of the CD4 receptor, monocytes and macrophages 
have been shown to express markers suitable for productive HIV-1 infection in vivo 
(Koenig et al., 1986). Although few macrophages are infected by HIV compared to 
CD4+ T cells, their phenotype, tissue localization and immune functions makes them 
an ideal immune cell type for infection and dissemination of the virus (Vijayan et al., 
2017, Sattentau and Stevenson, 2016). Therefore, macrophages play a critical role in 
the establishment of infection and pathogenesis of HIV. 
 
Gartner and colleagues were the first to report that tissue-resident macrophages are 
permissive to HIV infection and are capable of replicating the virus (Gartner et al., 
1986). Their study not only reported that HIV does not induce a sudden decrease in 
macrophage cell numbers but also showed that there is prolonged viral replication 
compared to the infection of CD4+ T cells. HIV infection of tissue macrophages which 
persists during combination antiretroviral therapy (cART) has been confirmed at all 
stages of the disease (Cory et al., 2013). Macrophage infection by HIV is not only 
dependent on CCR5 or CXCR4 surface expression; it also requires initial absorption 
of the virus by the cell surface. This process is facilitated by lectin-like receptors, 
integrin, and heparin sulfate proteoglycans (DiFronzo et al., 1997, Duncan and 
Sattentau, 2011). It was suggested that entry occurs after virion internalization in 
macropinosomes (Marechal et al., 2001) and endosomes where fusion between the 
viral envelope and the host is believed to occur (van Wilgenburg et al., 2014). In 
support of these findings, a recent study demonstrated that internalization of 
fluorescent quantum dots encapsulated by infectious HIV-1 particles in primary 
macrophages (Li et al., 2017).  
 
Upon productive HIV-infection of tissue-resident macrophages, they migrate from the 
mucosal sites of infection to regional lymph nodes where the virus disseminates 
systemically in the host (Rodrigues et al., 2017). In humans, this process is not very 
well understood and is impractical to investigate. However, in nonhuman primates 
such as Simian Immunodeficiency Virus (SIV)-infected rhesus macaques, the virus 
was detected as early as day 1 post intravaginal inoculation in the gastrointestinal tract 
and the spleen, and systemic distribution was observed at day 7 (Barouch et al., 2016). 
This viral dissemination is accompanied by an acute phase of HIV infection with rapid 
viral replication in many tissues (Li et al., 2005, Mattapallil et al., 2005). These findings 
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support the involvement of HIV-1 infected macrophages in systemic distribution of the 
virus. 
 
1.5.3. Macrophages contribute to the HIV-1 cellular 
reservoir 
 
The myeloid lineage cells play an essential role in HIV-1 infection and; continuously 
aid in its pathogenesis throughout disease progression (Kedzierska and Crowe, 2002). 
Immune functions of macrophages and their susceptibility to infection prompted 
numerous studies to investigate their role in the development of viral reservoirs and 
chronic inflammation observed in HIV-infected individuals on ART (Sereti et al., 2017, 
Hunt, 2017). ART drastically reduces HIV replication in the body. However, the virus 
has been shown to persist in cellular and anatomical reservoirs (Chun et al., 1997, 
Finzi et al., 1997, Wong et al., 1997, Sennepin et al., 2018, Su et al., 2018). When 
ART is interrupted, these reservoirs become a source of viral rebound. Viral reservoirs 
represent a major obstacle to the eradication of HIV (Rose et al., 2018). Ubiquitous 
distribution of macrophages in human tissues and their ability to infiltrate virtually all 
organs of the human body makes them an integral HIV target cell for spreading HIV-
1 in an infected individual (Gras and Kaul, 2010) and for establishing the development 
of the cellular viral reservoirs (Meltzer et al., 1990, Poles et al., 2006). 
 
The macrophage viral reservoirs cannot be controlled by current ART regimens 
because macrophages have a longer lifespan and are resistant to the cytopathic 
effects of viral replication (Barton et al., 2016). Although latently infected CD4+ T cell 
populations such as naïve T cells and memory T cells have been reported to be a 
source of HIV reservoir  (Blankson et al., 2002, Chun and Fauci, 1999, Finzi and 
Siliciano, 1998), various tissue-specific macrophage populations have also been 
implicated (Wong and Yukl, 2016). In macrophages, viral replication is much slower 
compared to CD4+ T cells; therefore, they express less viral proteins which enables 
them to evade the immune response (Alexaki et al., 2008). 
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1.6. Polarisation of Macrophages  
 
1.6.1. Polarisation of Macrophages 
 
Macrophages play a role in virtually every aspect of an organism’s biology, from 
development and homeostasis to tissue repair and immune responses to pathogens. 
They are a heterogeneous population of immune cells that constantly change their 
functional state in response to changes in tissue physiology or environmental 
challenges (Martinez and Gordon, 2014a). Their plasticity allows them to respond to 
various environmental signals and change their phenotype and physiology in response 
to cytokines and microbial signals (Mosser and Edwards, 2008). Macrophages are 
tissue-resident immune cells that perform crucial immunological functions such as 
antigen presentation, phagocytosis, cytokine secretion, and coordination of innate and 
adaptive immune responses (Fujiwara et al., 2011). For the longest time, tissue-
resident macrophages were believed to be continuously replenished by blood-
circulating monocytes that originate from progenitors in adult bone marrow. This 
concept was central in defining the “Mononuclear Phagocyte System” (MPS) that 
grouped together precursors of monocytes in the bone marrow, monocytes in the 
peripheral blood, and macrophages in the tissues (van Furth et al., 1972, Yona and 
Gordon, 2015). Advanced techniques for studying cellular ontogeny showed that the 
homeostatic contribution of peripheral blood monocytes to tissue-resident 
macrophage populations may be confined to specific tissues such the gut, the dermis, 
and the heart with tissue-specific turnover rate. Alternatively, most tissue-resident 
macrophages arise from embryonic precursors prior to birth and maintain themselves 
locally throughout adulthood, independent of circulating monocytes (Hoeffel and 
Ginhoux, 2015, Ginhoux and Guilliams, 2016). 
 
The functional maturation of macrophages has recently been described in a manner 
similar to the well-characterized concept of T helper type 1 (TH1) and T helper type 2 
(TH2) polarisation of CD4+ T cells (Romagnani et al., 2000, Mills et al., 2000). They 
are classified as M1 (classically activated) and M2 (alternatively activated) 
macrophages (Biswas and Mantovani, 2010, Gordon, 2003), M1-like macrophages 
secrete pro-inflammatory cytokines, mediate resistance to pathogens and contribute 
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to tissue destruction, while M2 macrophages secrete anti-inflammatory cytokines and 
promote tissue repair and remodeling (Gordon, 2003, Martinez et al., 2008). However, 
this paradigm of macrophage activation has not yet been fully characterized, 
especially in humans (Martinez and Gordon, 2014a). This definition only considered 
the effects of stimuli on macrophage polarisation neglecting complex mechanisms that 
lead to macrophage activation in different tissues. A great variety of intermediates 
have been described based on their plasticity and adaptability (Mosser and Edwards, 
2008) so that this simplistic concept has to be revised. One M1-like phenotype has 
been described compared with several of the M2 phenotypes, such as M2a, M2b, M2c 
and M2d (Mantovani et al., 2004, Ferrante et al., 2013). The M2b macrophages share 
similar characteristics with M1-like macrophages (Sironi et al., 2006). Each of the M2 
macrophages subtypes differs in a number of aspects such as expression of certain 
surface molecules, cytokine secretion, and function (Mosser and Edwards, 2008).  
 
1.6.2. Classical activation of Macrophages 
 
Classically-activated (M1) macrophage stimuli can be grouped according to their 
ability to induce prototypic inflammatory responses and markers. However, their 
source, role, receptor, and signaling pathways differ dramatically (Martinez et al., 
2008). The M1 phenotype results from stimulation of resting macrophages by 
microbial products or pro-inflammatory cytokines such as interferon–gamma (IFN-), 
tumor necrosis factor (TNF) or Toll-like receptor (TLR), characteristically, they have 
been shown to produce high levels of IL-12, IL-13, and nitric oxide (NO) (Verreck et 
al., 2004). Interferon regulatory factor-5 (IRF-5) is a transcriptional regulator of the M1 
macrophage phenotype and has been shown to play a critical role in the induction of 
pro-inflammatory cytokines such as TNF, IL-6, IL-12 and IL-33 (Krausgruber et al., 
2010b). There is a high expression of IRF-5 in human M1 macrophages which adds 
to the plasticity and polarisation of macrophages to the M1 phenotype and initiation of 
potent TH1-TH17 responses (Krausgruber et al., 2011b). Interestingly, IRF5 has the 
ability to promote differential gene expression suggesting a mechanism by which IRF5 
can form either repressor or activator complexes at selected target genes (Eames et 
al., 2012). In human macrophages, prostaglandin E2 (PGE2) and cyclooxygenase 
(Cox) enzymes contribute to the production of pro-inflammatory cytokines (Arias-
  16 
Negrete et al., 1995). Cox-1 and Cox-2 initiate PGE2 synthesis by catalyzing the first 
two steps of eicosanoid metabolism using arachidonic acid as a predominant 
substrate (Williams and Shacter, 1997). Cox enzymes are indistinguishable in their 
biosynthetic catalytic activities, however, they have been shown to have different 
physiological functions. Cox-1 (prostaglandin synthase-1) protein is constitutively 
expressed in most cell types and is thought to be responsible for regulating normal 
physiological functions and its cellular activity is primarily regulated by substrate 
availability while Cox-2 is an inducible enzyme expressed by activated macrophages 
and fibroblasts (Giroux and Descoteaux, 2000). 
 
1.6.3. Alternative activation of Macrophages 
 
There are four subtypes of M2 macrophages that have been described so far, these 
are interrelated and have been termed M2a, M2b, M2c and M2d. They have various 
functions including regulation of immunity, maintenance of tolerance, inhibition of 
inflammation and tissue repair or wound healing (Martinez and Gordon, 2014b). 
Exposure to glucocorticoids and cytokines such as interleukin (IL)-4, IL-10 and IL-13 
has been shown to polarize macrophages towards the M2 subset (Gordon, 2003). M2 
polarized macrophages are characterized by enhanced expression of innate immunity 
receptors, which includes scavenger receptors such as CD163 and the macrophage 
mannose receptor CD206 and also by an up-regulation in arginase activity which 
counteracts nitric oxide (NO) synthesis (Munder et al., 1998). CD68 and CD163 are 
markers used to identify macrophages in tissue sections (Barros et al., 2013). Several 
in vitro studies suggested CD163 as a possible marker for M2 macrophages (Sica and 
Mantovani, 2012, Buechler et al., 2000, Sulahian et al., 2000) and other studies of 
immune tissues considered CD163+ cells identified by immunohistochemistry as M2 
macrophages (Zaki et al., 2011, Ino et al., 2013). CD206, a macrophage mannose 
receptor has been shown to be upregulated by IL-4 supporting the concept of 
alternative activation of macrophages (Stein et al., 1992). A schematic diagram 
depicting the polarisation of macrophages based on the M1/M2 paradigm is shown in 
Figure 1.7. 
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Figure 1.7: An overview of macrophages polarisation into M1 and M2. Resting 
macrophages (M0) can be classically activated by IFN- or lipopolysaccharide (LPS) 
stimulation into M1 macrophages. M1 macrophages are responsible for pro-
inflammatory cytokine secretion, phagocytosis and initiation of immune response. 
Treatment of M1 macrophages with IL-6 or adenosine switches their polarisations 
towards an M2-like phenotype termed, M2d (Ferrante et al., 2013). IL-4, IL-1R and IL-
10 stimulation polarizes M0 macrophages towards M2a, M2b, M2c respectively. M2 
macrophages secrete high levels of the immune regulatory cytokine, IL-10 while 
expressing markers such as CD163, CD206 and CD209. (Created with Bio-render) 
 
1.6.4. HIV-1 infection of polarized macrophages 
 
Viral replication upon macrophage infection is regulated by cytokines that activate 
and/or polarize macrophages (Jimenez et al., 2012). Depending on the state of the 
cell at the time of infection, macrophage polarizing cytokines could either enhance or 
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inhibit HIV-1 replication (Cassol et al., 2010). Numerous studies have shown that HIV-
1 infection of alternatively activated macrophages resulted in significantly lower levels 
of reverse transcription and p24 production (Montaner et al., 1997, Schuitemaker et 
al., 1992, Wang et al., 1998). However, treatment of these macrophages with IL-4, 
increased viral replication (Kazazi et al., 1992, Naif et al., 1994). Cassol et al., and 
others have also shown that cytokine-induced polarisation of human monocyte-
derived macrophages (MDMs) into either classical (M1) or alternatively (M2a) MDM 
was associated with decreased capacity to support productive CCR-5-dependent HIV-
1 infection (Cassol et al., 2009). They also reported an increased inhibition of viral 
replication in MDMs that were stimulated with INF-, IL-4, IL10 and IL-33 (Cassol et 
al., 2009, Cassol et al., 2010, Rasool et al., 2008). Classically-activated macrophages 
secrete high levels of pro-inflammatory cytokines which aid in HIV-infection of these 
cells and disease pathogenesis (Herbein and Varin, 2010). Alternative activation of 
macrophages induced by IL-4 and IL-13 decreases their susceptibility to HIV-1 
infection through down-regulation of CCR5 expression (Wang et al., 1998). HIV-1 
infection of MDMs has been associated with increased secretion of M1-associated 
chemokines such as CCL3, CCL4, and CCL5; and decreased expression of M2-
associated markers, such as CD163, and CD206 (Brown et al., 2008, Porcheray et 
al., 2006). These findings further reinforce the hypothesis that HIV-1 infection of 
macrophages polarizes them towards an inflammatory (M1) phenotype which 
enhances disease progression. Whether pre-existing polarized M1 macrophages (due 
to inflammation) are more susceptible to HIV-1 infection is not yet clear. 
 
1.7. The immunology of pregnancy 
 
1.7.1. The Maternal Foetal Interface 
 
Pregnancy presents a great challenge to the maternal immune system. It is a unique 
and complex immunological phenomenon in that a foetus consisting of both maternal 
and paternal alleles, develops within an active maternal immune system without 
succumbing to immunological rejection (Gomez-Lopez et al., 2014, Erlebacher, 
2013a). This occurs simultaneously with defense against pathogenic microorganisms 
(PrabhuDas et al., 2015). It represents a complex immunological paradox that has 
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been the focus of numerous research for over half a century. The maternal-foetal 
interface is a unique anatomical site between the uterine mucosa and the extra-
embryonic tissue of the developing conceptus (Erlebacher, 2013a). It is made-up of 
three well-defined compartments, namely the placenta (foetal origin), the decidua and 
myometrium (both of maternal origin) which are both infiltrated by extra-villous 
trophoblasts (EVT) during implantation. During gestation, these compartments 
undergo drastic changes in architecture and leukocyte composition (Brown et al., 
2014, Gomez-Lopez et al., 2014).  
 
Flow cytometric analysis studies have shown that 40% of the cell populations in the 
decidua are leukocytes (Vince et al., 1990). At conception, there is a general increase 
in immune cell populations, such as Natural Killer (NK) cells and macrophages at the 
maternal-foetal interface (Heikkinen et al., 2003). In normal conditions, most decidual 
macrophages are characterized by an immunosuppressive phenotype with M2 
polarisation (Svensson et al., 2011) whereas, in complicated pregnancy, there is an 
increase of pro-inflammatory M1 macrophages (Kacerovsky et al., 2014). We recently 
highlighted the lack of consensus in literature on the impact of complications of 
pregnancy on the activation status of macrophage populations in the maternal-foetal 
interface (Zulu et al., 2019, Journal of Innate immunity, in press). Macrophages are 
the most abundant antigen presenting cells (APCs) in the human decidua during 
pregnancy (Nagamatsu and Schust, 2010). They have been shown to play a role in 
regulating pregnancy (Abrahams et al., 2004), promoting tolerance of the semi-
allogeneic foetus (Svensson-Arvelund et al., 2014), and in the maintenance of a 
homeostatic environment necessary for normal foetal development (Erlebacher, 
2013b). There is limited knowledge about the quantities and characteristics of the 
potent type of APCs, the dendritic cells (DCs) at the maternal-foetal interface of 
humans throughout pregnancy. In mice models, uterine DCs were phenotypically 
characterized as cells with high expression of CD11c and MHCII surface molecules 
with lymph node-homing and T-cell-stimulating capacity (Collins et al., 2009, Keenihan 
and Robertson, 2004). Whereas in humans, decidual DCs isolated from first trimester 
decidua were described as cells expressing CD83 with potent antigen-presenting 
capacity ex vivo (Kammerer et al., 2000). The presence of phenotypically and 
functionally distinct DCs at the maternal-foetal interface of both humans and rodents 
has been proposed to contribute to tolerance and immunity (Liang and Horuzsko, 
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2003). However, more sophisticated procedures are required to characterize 
populations of DCs of the maternal-foetal interface and how they play a role in 
tolerance. 
 
 
1.7.2. The Placenta 
 
The placenta is a transient organ made-up of foetal-derived tissues and the maternal 
decidua which develops from the uterine mucosa (Ferreira et al., 2017). Placenta 
formation occurs through a complex but well-coordinated effort between the foetus’s 
extra embryonic tissues and the gravid endometrial tissues. In humans, it is a disc-
shaped organ with a diameter of 15-20cm, thickness of 2-3cm and weighs 
approximately 500g at term (Griffiths and Campbell, 2015). It plays a crucial role in 
orchestrating the local circulatory system, provides a large surface area for maternal-
foetal exchange, and also acts as an immune regulatory tissue during pregnancy 
(Wetzka et al., 1997). Therefore, the placenta is a major interface between the mother 
and the developing foetus, where its functions include gaseous exchange, nutrients 
transfer, excretion of waste products, and foetal protection through hormone secretion 
and transfer of immunity from the mother to the foetus (Knipp et al., 1999, Malek, 
2013). The placenta acts as a semi-permeable membrane that allows for transfer of 
certain drugs across the placental membranes depending on the physical properties 
the drugs (Pacifici and Nottoli, 1995, van der Aa et al., 1998). 
 
During embryo implantation, the uterine mucosa undergoes a specialized tissue 
reaction known as decidualization to support the development and function of the 
placenta. The decidua is therefore the specialized endometrial stromal tissue 
surrounding the conceptus (Erlebacher, 2014). Trophoblasts are the extraembryonic 
epithelial cells that compose the bulk of the placenta and replace maternal endothelial 
cells in remodeled spiral arterioles. There are two types of villi in the placenta, the villi 
that float in the maternal blood and the villi that attach the foetus to the mother’s 
endometrial wall. Each villus has a connective tissue core which contains foetal blood 
vessels and many macrophages, called Hofbauer cells found under a thick basement 
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membrane (Pereira et al., 2005). A schematic diagram of a transverse section through 
a full-term placenta is shown in Figure 1.8. 
 
 
Figure 1.8: A schematic diagram of a transverse section through a full-term placenta. 
(Created using Bio-render). 
 
1.7.3. Maternal-Foetal Tolerance 
 
The mechanism by which the maternal immune system tolerates the foetus is not yet 
fully understood. Successful pregnancy is facilitated and is dependent on continual 
development of maternal-foetal tolerance (Finn et al., 1977). It has been 66 years 
since Medawar (Medawar, 1953) proposed the presence of immunological tolerance 
towards the semi-allogeneic foetus. Initially, it was proposed that immune tolerance is 
brought about by the failure of maternal immune cells to respond to foetal cells 
expressing foreign molecules (Medawar, 1953). However, It was later shown that, 
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pregnancy induces the development of foetal antigen-specific cytotoxic T cells and 
antibody-mediated immune responses against the paternal-derived HLA class I 
antigens of the foetus (van Kampen et al., 2002). These immune responses are 
suppressed through the modulation of effector T cells and NK cells functions at the 
maternal-foetal interface by the induction of regulatory T cells (Tregs)-specific for 
foetal antigens (Tilburgs et al., 2008, Tilburgs et al., 2009, Samstein et al., 2012).  
 
Numerous other mechanisms on how the foetus is protected from maternal immunity 
have been proposed. These include catabolism of tryptophan, an amino acid involved 
in T lymphocytes activation by the enzyme indole-amine 2,3-dioxygenase (IDO) 
secreted by trophoblasts and macrophages (Munn et al., 1998); trophoblast cell 
induced tolerance through expression of certain MHC molecules (King et al., 2000, 
Ishitani et al., 2003); and various mechanisms induced by regulatory T lymphocytes 
(Tregs) have been proposed  (Aluvihare et al., 2004, Sasaki et al., 2005, Somerset et 
al., 2004). The EVTs that infiltrate the maternal decidua during implantation lack the 
expression of classical MHC class I molecules, HLA-A and HLA-B like most cells, but 
express HLA-C and the non-classical MHC class I molecules HLA-E and HLA-G (Apps 
et al., 2009). HLA-G is specifically expressed by EVT and has low levels of 
polymorphism suggesting that it may play a role in the induction of immune tolerance 
at the maternal-foetal interface (Kovats et al., 1990). 
 
Several studies have reported the critical role of decidual macrophages in the 
induction and maintenance of immune tolerance. Svensson-Arvelund and colleagues 
reported that placental trophoblast cells secrete IL-10 and M-CSF which polarizes the 
decidual macrophages (maternal-derived) towards the homeostatic, immune 
regulatory M2 phenotype; so leading to an expansion of regulatory T cells (Tregs) and 
inhibition of T helper cells activation. Collectively, these cells contribute to foetal 
tolerance and maintenance of a homeostatic microenvironment suitable for foetal 
development (Svensson-Arvelund et al., 2014). Figure 1.9. is an illustration of the 
mechanism that decidual macrophages interact with decidual NK cells and T cells to 
bring about maternal-foetal immune tolerance. 
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Figure 1.9: The interaction of decidual macrophage (DMs) with decidual NK cells and 
T cells to bring about maternal-foetal tolerance (Tang et al., 2015). DMs stimulate the 
differentiation of endometrial NK cells into activated decidual NK (dNK) cells by 
secreting IL-15. DMs interact with dNK cells via CD209 (DC-SIGN), leading to the 
secretion of IFN- that then stimulates the up-regulation of IDO in DMs. IDO 
catabolizes tryptophan leading to impaired T cell activation and expansion of Tregs. 
Tregs interact with DMs via CTLA-4/B7-1/2, further upregulating the production of IDO. 
DMs suppress excessive T cell activation via B7/H1/PD-1 interactions. 
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1.8. The role of macrophages in pregnancy 
 
1.8.1. Decidual Macrophages 
 
Following embryo implantation, the decidua divides into two distinct regions: the 
decidua basalis, which is the portion of the uterus attached to the placenta, and 
decidua parietalis, which is the layer closest to the endometrium, found between the 
amnion and the chorion (Brown et al., 2014). Macrophages derived from both the 
mother and foetus play a very important role in all stages of pregnancy. Labour is an 
inflammatory process (Bollopragada et al., 2009) and presence of inflammatory 
macrophages has been shown in the decidua, cervix and foetal membranes during 
labour (Osman et al., 2003). Macrophages are among the primary innate immune cells 
that play a role in the processes of term and preterm labour (Houser, 2012). Decidual 
macrophages are the most abundant antigen presenting cells (APCs) throughout 
gestation (Bartmann et al., 2014), and they constitute more than 15% of CD45+ cells 
or at least 10% of all decidual cells (Vince et al., 1990, Singh et al., 2005). They are 
critical in establishing the balance between tolerance and pro-inflammatory 
responses. According to Heikkinen et al they are phenotypically characterized by co-
expression of CD14 and CD68 (Heikkinen et al., 2003). They have been shown to 
have characteristics associated with homeostatic M2 macrophages, including 
expression of the homeostatic scavenger receptor CD163 and the pattern recognition 
receptors CD206 and CD209 while preferentially secreting cytokines and chemokines 
such as IL-10, CCL-2 and CCL-18 (Svensson et al., 2011, Houser et al., 2011). Human 
decidual macrophages were recently characterized as CD163+CD206+CD209+IL-
10+CCL18+ cells (Svensson-Arvelund et al., 2014, Sayama et al., 2013). 
 
1.8.2. Hofbauer Cells 
 
Hofbauer Cells (HCs)  are foetal-derived macrophages found within the chorionic villi 
of the placenta (Goldstein et al., 1988, Reyes et al., 2017, Kim et al., 2008). These 
cells express all three subtypes of the IgG Fc receptors (FcR) found on human 
leukocytes and classical monocyte/macrophage markers, such as CD68 (Vinnars et 
al., 2010, Bright et al., 1994). They were identified more than 100 years ago as large 
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(10-30µm), pleomorphic cells, highly vacuolated with granular cytoplasm that is 
associated with phagocytic activity (Castellucci et al., 1980, Castellucci et al., 2000, 
Enders and King, 1970). Histological analyses of normal placental beds showed a 
large number of macrophages, localized and within the vicinity of apoptotic cells (De 
and Wood, 1990).  
 
Although their ontogeny of HCs is poorly characterized, they are found within the foetal 
villi of the placenta from the first trimester of pregnancy until birth (Wetzka et al., 1997). 
During the first trimester of pregnancy, they are believed to originate from 
mesenchymal progenitor cells (Abumaree et al., 2013) while in the second and third 
trimester, they differentiate from circulating monocytes of the foetus (Selkov et al., 
2013, Moskalewski et al., 1975). Their role in placental physiology is also not well 
understood; however, there is some evidence that they may play a role in transport 
within the villous stroma and in immunological reactions through their Fc receptors 
(Jensen and Matre, 1995, Saji et al., 1994). Histological analyses showed their 
location to be in the stroma of the placental villus, close to foetal vessels and 
trophoblasts making them likely candidates for involvement in regulatory functions 
during placental development and homeostasis (Katabuchi, 2014).  
 
HCs have a regulatory phenotype consistent with that of M2 anti-inflammatory 
macrophages. Several studies have shown that HCs are stimulated by glucocorticoids 
(Tang et al., 2013) and IL-10 (Svensson et al., 2011) to express CD163, CD206 and 
CD209 (Svensson et al., 2011) while secreting IL-10 and TGF- (Johnson and 
Chakraborty, 2012). HCs have also been reported to constitute a mixture of M2a, M2b 
and M2c macrophages that differ in surface expression of certain molecules, in 
cytokine secretion and functions (Loegl et al., 2016). Functionally, HCs have been 
shown to play a critical role in maternal immunological tolerance against the foetus 
(Svensson-Arvelund et al., 2015). This further reinforce the regulatory rather than the 
inflammatory role of HCs. Hofbauer cell dysfunction is associated with numerous 
pregnancy complications such as chorioamnionitis, miscarriage, and preterm delivery 
(Tang et al., 2011), highlighting that these cells play an important role in maintaining 
a healthy pregnancy. Numerous publications reporting on the polarity and function of 
maternal decidual macrophages have been thoroughly reviewed by Brown et al. and 
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others (Brown et al., 2014).  However, there is very little information on the effect of 
complications of pregnancy and maternal infections on foetal HCs polarity, function 
and gene expression profile. 
 
HCs have been shown to limit HIV-1 replication by the induction of immuno-regulatory 
cytokines (Johnson and Chakraborty, 2012) and they also possess intrinsic 
adaptations which facilitate the sequestration of HIV-1 that may serve as a protective 
viral reservoir to allow for antiretroviral drug entry in utero and potentially the 
neutralization of the virus (Johnson et al., 2015). Therefore, HCs are pivotal mediators 
in HIV-1 transmission in utero. Although in vitro permissiveness of HCs to HIV-1 
infection has been reported (Al-Husaini, 2009), there is a paucity of data on the effect 
of HIV-1 and/or antiretroviral drugs exposure on the quantity, phenotype and function 
of both decidual macrophages and HCs in placentas from pregnancies complicated 
by maternal HIV-1 infection. 
 
1.9. HIV-1 infection and Pregnancy 
 
1.9.1. Impact of HIV infection on birth outcomes 
 
During pregnancy, the mechanism of trans-placental transmission of HIV-1 from the 
mother to her foetus is still not yet clear. However, in a few cases, vertical transmission 
of HIV was reported to be due to trans-placental spread by an unknown mechanism 
(Newell, 1998). Apart from transmission of the virus from the mother to her foetus, a 
number of studies have reported a significant association between maternal HIV-1 
infection and adverse birth outcomes (Newell et al., 1994, Coley et al., 2001, Miotti et 
al., 1990, Braddick et al., 1990, Johnstone, 1992). Small-for-gestational age (SGA) 
infants, stillbirth, preterm birth and intrauterine growth retardation (UIGR) which leads 
to perinatal and neonatal mortality and morbidity have all been reported in pregnancies 
complicated by HIV-1 infection regardless of transmission (Dos Reis et al., 2015, 
Ndirangu et al., 2012, Chetty et al., 2018, Jao et al., 2012).  
 
Numerous studies have reported the transfer of maternal immune cells and humoral 
immunity across the placenta into the foetal circulation (Mold et al., 2008, Nijagal et 
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al., 2011, Zhou et al., 2000). During maternal HIV-1 infection, antibody- and cell-
associated HIV-1 virions, cell-free virions and maternal broadly neutralizing antibodies 
cross the placental barrier to interact with Hofbauer cells (HCs) prior to entering the 
foetal circulation (Palmeira et al., 2012). The phenotype of HCs favors productive 
infection with HIV-1 (Simister, 1998). Despite this, vertical transmission of HIV-1 is 
very low and that is mainly attributed to the widespread use of ART. Combination 
antiretroviral therapy has significantly improved mortality and slowed disease 
progression amongst HIV infected individuals. It has also been associated with life-
threatening, non-AIDS health complications such as cardiovascular diseases, 
malignancies, and neurological diseases (Hasse et al., 2011, Guaraldi et al., 2011) 
and adverse birth outcomes, as discussed above. 
 
1.9.2. Classes of antiretroviral drugs 
 
There are 6 classes of antiretroviral drugs that are currently prescribed to HIV-1 
infected individuals (Meintjes et al., 2017). These drugs target different stages of HIV 
replication cycle. They are as follows: 
1) Nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs). 
2) Non-nucleoside reverse transcriptase inhibitors (NNRTIs). 
3) Protease inhibitors (PIs). 
4) Integrase strand transfer inhibitors (INSTIs). 
5) Fusion inhibitors (FIs). 
6) Chemokine receptor antagonists (CCR5 Antagonist). 
 
In South Africa, an ART regimen usually consists of two NRTIs [tenofovir (TDF) and 
emtricitabine (FTC)] and a third drug, either from the NNRTIs [efavirenz (EFV)] or the 
PIs class of antiretroviral (ARV) drugs. It is not yet known whether metabolites of these 
drugs are able to cross the placental barrier, also the long term effects of these drugs 
on foetal and neonatal immunity are poorly understood. The ART regimens currently 
available in southern Africa are made-up of the ARV drugs summarized in Table 1 
(Meintjes et al., 2017). 
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Table 1.1: Characteristics of ARV drugs currently prescribed in southern Africa. 
Class of drug Generic name Recommended dosage 
NRTI Tenofovir (TDF) 300 mg, daily 
NRTI Lamivudine (3TC) 300 mg, daily 
NRTI Emtricitabine 200 mg, daily 
NRTI Abacavir (ABC) 300 mg, 12-hourly 
NRTI Zidovudine (AZT) 300 mg, 12-hourly 
NRTI Stavudine (d4T) 300 mg, 12-hourly 
NRTI Didanosine (ddI) 400 mg, daily 
NNRTI Efavirenz (EFV) 600 mg at night 
NNRTI Nevirapine (NVP) 200 mg, 12-hourly 
NNRTI Rilpivirine (RPV) 25 mg, 12-hourly 
NNRTI Etravirine (ETR) 200 mg, 12-hourly 
PI Atazanavir (ATV) 400 mg, daily 
Boosted PI Lopinavir/ritonavir (LPV/r) 400/100 mg, 12-hourly 
PI Darunavir 600 mg, 12-hourly 
PI Saquinavir (SQV) 1000mg, 12-hourly 
InSTI Raltegravir 400 mg, 12-hourly 
InSTI Dolutegravir (DTG) 50 mg, daily 
CCR5 blocker Miraviroc (MVC) 150 mg, daily 
 
 
1.9.3. Antiretroviral therapy and birth outcomes 
 
Among pregnant women, studies have reported an increased rate of adverse birth 
outcomes with maternal highly active antiretroviral therapy (HAART) (Thorne et al., 
2004, Papp et al., 2014, Mofenson, 2016). There is a high prevalence of preeclampsia 
and foetal death amongst HIV-1 infected women on combination antiretroviral therapy 
(cART), and ART has been shown to aggravate pre-eclampsia (Tooke et al., 2016).  
A South African based, cohort study by Chetty and colleagues showed no association 
between preconception and post-conception use of non-nucleoside reverse 
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transcriptase-based regimens tenofovir disoproxil fumarate (TDF)-lamivudine 
(3TC)/emtricitabine (FTC)-efavirenz (EFV) on preterm birth and small-for-gestational 
(SGA) infant births compared to other regimens (Chetty et al., 2018). However, 
another study comparing birth outcomes among women initiating dolutegravir-based 
ART with women initiating efavirenz-based ART, reported that initiation of 
dolutegravir-based therapy during pregnancy may be associated with a major 
congenital abnormality called skeletal dysplasia, (Zash et al., 2018). The aetiology of 
adverse birth outcomes among HIV-infected women on ART and how different ART 
regimens interact with cells of the maternal-foetal interface is yet to be fully 
understood.  
 
In this PhD, It is hypothesized that HIV-1 and/ ART exposure, given either before or 
during pregnancy, dysregulates the balance of M1 and M2 macrophages at the 
maternal-foetal interface leading to adverse birth outcomes. The following questions 
were asked: 
1). How does the duration of ART exposure affect the phenotype and polarisation of 
decidual macrophages and Hofbauer cells in HIV-1 infected, South African women? 
2). What markers can be used to characterize and differentiate between decidual 
macrophages and Hofbauer cells irrespective of their tissue localization? 
3). What are the decidual macrophage and Hofbauer cell-specific biomarkers of HIV-
1 infection? 
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2. Study Aim & Objectives 
 
Study Aim: To investigate the impact of HIV-1 and antiretroviral drug exposure on the 
phenotype and function of maternal uterine-derived, decidual macrophages and foetal 
placental-derived macrophages, the Hofbauer cells. 
 
Objective 1: To phenotypically characterize decidual macrophages and Hofbauer 
cells from placentas of HIV-1 infected women who initiated antiretroviral therapy 
during pregnancy (Initiating ART) and before pregnancy (Stable ART) using 
immunohistochemistry and immunofluorescence staining. 
 
Objective 2: To identify novel cell markers for decidual macrophages and Hofbauer 
cells based on the Human Protein Atlas database. 
 
Objective 3: To determine placental macrophage-specific biomarkers of maternal 
HIV-infection and activation status based on microarray datasets generated from 
monocyte-derived macrophages (MDM) that were stimulated with various stimuli and 
infected with CCR5-using (R5) HIV-1.
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3. Materials and Methods 
 
3.1. Human Placentas 
 
Placentas (n=30) used in this study came from the Prematurity Immunology in HIV-
infected Mothers and their infants Study (PIMS) cohort based in Cape Town, South 
Africa. The PIMS cohort consisted of HIV-1 infected pregnant women who were 
already on combination antiretroviral therapy (cART) before pregnancy and HIV-1 
infected women who initiated cART at week 20 during gestation. Placentas used in 
this study were collected under a protocol approved by the University of Cape Town, 
Faculty of Health Sciences, Human Research Ethics Committee (HREC REF: 
739/2014). Placentas were collected at birth from consenting mothers by midwives 
and transported to the University of Cape Town, Division of Immunology Laboratory 
in a sealed container submerged in 500ml of RPMI 1640 medium (Sigma-Aldrich, St. 
Louis, MO, USA) supplemented with 10% foetal-calf serum (FCS) and 1% 
penicillin/streptomycin antibiotic (Life Technologies, Grand Island, NY, USA) 
(complete medium). This study subset received ethical approval (HREC REF: 
665/2015). 
 
3.2. Isolation of decidual macrophages and Hofbauer cells 
 
Decidual leukocytes and Hofbauer cells were isolated from the decidual membrane 
and placental foetal-chorionic villi respectively. The Decidua Parietalis (DP) was 
obtained by firstly removing the amnion before scraping the DP off from chorion while 
Decidua Basalis (DB) was obtained from the maternal side of the basal plate. The 
Villous Tissue (VT) was obtained from the basal plate of the placenta. The dissection 
of membranes of the maternal-foetal interface from a term human placenta is 
illustrated in Figure 3.1. After dissection, the DP, DB and VT were rinsed in phosphate 
buffered saline (1X PBS) (Sigma-Aldrich, St. Louis, MO) and minced using scissors. 
Finely minced tissues were then incubated in 1% Collagenase IV (1 mg/ml) (Sigma-
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Aldrich, St. Louis, MO, USA) and 0.1% DNase I (0.1 mg/ml) (Sigma-Aldrich, St. Louis, 
MO, USA) in a shaking water bath at 370C for 75 minutes. After digestion, tissues were 
washed in complete medium and filtered through a 100m, 70m and 40m pore cell 
strainers (Falcon; Corning Life Sciences, Durham, NC, USA) successively into a 50ml 
falcon tube. The resulting cell suspension was washed and re-suspended in 10ml of 
complete medium and then added into 10ml of 50% Percoll solution (GE Healthcare 
Biosciences, Uppsala, Sweden). The 20ml of the sample in Percoll solution was 
carefully layered on top of the 45% Percoll in PBS phase that was already layered on 
top of the 70% Percoll in RPMI medium. The resulting Percoll gradient was then 
topped up with 5ml of 1X PBS before gradient centrifugation (2000rpm for 25 minutes). 
Decidual macrophages and Hofbauer cells were collected from the interface higher 
than the lymphocytes layer of the density gradient (Figure 3.2) and washed twice in 
1X PBS supplemented with 1% FCS. The following protocol was optimized for the 
isolation of Hofbauer cells and decidual macrophages from the maternal-foetal 
interface. 
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Figure 3.1: Dissection of placental membranes and isolation of leukocytes from the 
maternal-foetal interface of term human placenta (Xu et al., 2015). (A) Dissection of 
basal plate from the placenta; (B) Separation of the basal plate from the placental villi; 
(C) Trimming of the placental villi from the decidua basalis; (D) Rinsing of the decidual 
basalis in 1x PBS; (E) A piece of the chorionic membrane is dissected; (F) Decidua 
parietalis is gently scrapped-off to remove blood clots; and (G) Decidua parietalis 
(dotted line) is separated from the chorionic membrane. 
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Figure 3.2: Percoll gradient layers after centrifugation for the isolation of decidual 
macrophages and Hofbauer cells. 
 
3.3. Fixation of decidual macrophages and Hofbauer cells 
 
Placenta-isolated decidual macrophages and Hofbauer Cells were stained with a 
Live/Dead cell marker, Zombie NIR Fixable Viability Kit (Biolegend, San Diego, CA) 
prior to fixing. The kit is composed of lyophilized Zombie NIR dye and anhydrous 
DMSO. A standard cell staining protocol was followed whereby cells were re-
suspended at 1.0 x 106 cells per 100l of 1x PBS before adding 1l of zombie NIR dye 
and incubating at room temperature for 20 minutes. Cells were then washed twice in 
RPMI medium (2100rpm for 3 minutes). After removing supernatant, cells were then 
incubated in 10ml of 1x BD FACSTM lysing solution (BD Biosciences, San Jose, CA) 
which lyses red blood cells while fixing the remaining blood cells and incubated at 
room temperature for 10 minutes. Cells were then washed in 1x PBS containing 1% 
FCS and centrifuged 2100rpm for 3 minutes. After removing the supernatant, cells 
were frozen at 1 x 106 cells/ml in 10% DMSO and FCS. Cells were then stored in the 
-80oC freezer.  
 
3.4. Immunohistochemistry and Immunofluorescence 
 
Immunohistochemistry (IHC) is an extensively used technique in pathology. It 
combines the fields of anatomy, physiology, immunology and biochemistry. It is useful 
for visualizing the distribution and localization of specific-antigens or cellular 
components on tissues sections (Ramos-Vara, 2017). Immunofluorescence (IF) 
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staining is an extension of IHC which allows for localization of proteins in cells by 
immunofluorescence (Donaldson, 2015). In this study, IHC and IF were used to 
phenotypically characterize decidual macrophages and Hofbauer cells from placentas 
from HIV-1 infected mothers on cART from the two groups. Human placental DP, DB 
and VT were dissected from placentas and fixed in 10% formalin (10% Formaldehyde 
and 10g of anhydrous sodium chloride in distilled water) (KIMIX chemicals and lab 
Suppliers, Cape Town, South Africa) for at least 24 hours. Tissues were then trimmed 
and placed onto labelled tissue processing/embedding cassettes (Sigma-Aldrich, St. 
Louis, MO, USA) for processing on the Leica TP1020 processor (Leica Biosystems, 
Wetzler, Germany). After processing, placental tissues were embedded in paraffin on 
the Leica EG1140H (Leica Biosystems, Wetzler, Germany). Formalin-fixed paraffin-
embedded DP, DB and VT blocks were sectioned into 5m thick sections onto labeled-
Leica surgipath X-tra adhesive slides (Leica Biosystems, Wetzler, Germany) using the 
Leica Rotary Microtome (Leica Biosystems, Wetzler, Germany).  
 
For subsequent immunohistochemistry experiments, wax was removed from tissue 
slides using xylene and 100% ethanol. Endogenous peroxidase activity was blocked 
with methanol containing 0.3% H2O2 (Sigma-Aldrich, St. Louis, MO, USA) for 20 
minutes. Tissue sections were then rehydrated with 70% and 50% ethanol before 
antigen retrieval. Two different antigen retrieval methods were performed depending 
on the primary antibody data sheet. Tissue sections were pre-treated by microwaving 
the sections for 10 minutes in boiling citrate buffer (10mmlo/l, pH 6) (Sigma-Aldrich, 
St. Louis, MO, USA) or in boiling Tris/EDTA buffer (1mmol/l, pH 9) (Sigma-Aldrich, St. 
Louis, MO, USA). After two washes in PBS, tissue sections were incubated with 
primary antibodies at primary antibody-specific concentrations in PBS with 1% BSA 
(Sigma-Aldrich, St. Louis, MO, USA) at 40C overnight. Next day, tissue sections were 
washed three times in PBS and incubated for 30 minutes with the ultra-view universal 
DAB detection kit (DAB Substrate) (Agilent technologies, Santa Clara, CA, USA). 
Tissue sections were then counterstained with Mayer’s hematoxylin (Agilent 
Technologies, Santa Clara, CA, USA) for 4 minutes, and then washed for 5 minutes 
with distilled water. The slide was then covered with a coverslip using Entellan 
mounting medium (Sigma-Aldrich, St. Louis, MO, USA). Details of the primary 
antibodies used in IHC experiments are listed on Table 3.1.  
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Table 3.1: Details of primary antibodies used in IHC experiments. 
Primary 
Antibody 
Source Species Cat. 
Number 
Isotype Clone Antigen 
retrieval 
CD68 Abcam Mouse ab49777 IgG2a,  514H12 Tris/EDTA 
CD163 Abcam Rabbit ab189915 IgG EPR146
43-36 
Citrate 
CD206 Abcam Mouse ab117644 IgG1,  5C11 Citrate 
CD209 Abcam Rabbit ab5715 IgG 9E9A8 Tris/EDTA 
 
For Immunofluorescence experiments, wax was removed from tissue slides using 
xylene and 100% ethanol. Antigen retrieval was done using 10mM Citrate buffer (pH6) 
(Sigma-Aldrich, St. Louis, MO, USA) in a pre-heated pressure cooker for 2 minutes. 
After antigen retrieval, tissue slides were blocked in 5% normal goat serum (Sigma-
Aldrich, St. Louis, MO, USA) for 60 minutes in a humid chamber at room temperature. 
The blocking solution was then rinsed with PBS-Tween 20 (PBST) (Sigma-Aldrich, St. 
Louis, MO, USA). Tissue sections were incubated with the primary CD163 antibody at 
1:200 dilutions in PBST and incubated in the dark at room temperature for 90 minutes. 
After incubation with the primary antibody, tissue slides were washed three times with 
PBST. Slides were then incubated with the Cy3-labelled Donkey-anti-rabbit secondary 
antibody in the dark at room temperature for 30 minutes. After washing with PBST, 
tissues sections were permeabilised by staining with 0.1% Triton-X100 (Sigma-
Aldrich, St. Louis, MO, USA) for 10 minutes. Slides were washed three times with 
PBST and then stained with the second primary antibody, Alexa Fluor 488-conjugated 
IRF-5 at 1:100 dilutions. The slides were incubated at 4oC overnight in a moist 
chamber. Next day, slides were washed three times with PBST, stained with DAPI and 
incubated at room temperature for 20 minutes. Slides were washed twice with PBST, 
tissue autofluorescence was quenched with a solution of 0.1% Sudan Black B (Sigma-
Aldrich, St. Louis, MO, USA) in 70% ethanol, and incubated in the dark for 10 minutes. 
After washing with PBST, the slides were mounted using fluorescent mounting 
medium (Sigma-Aldrich, St. Louis, MO, USA), sealed, and stored at 4oC until image 
acquisition. As negative controls, corresponding slides were concurrently stained with 
universal isotype control, Rabbit IgG for both markers. 
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Table 3.2: Details of primary antibodies used for IF experiments. 
Primary 
Antibody 
Source Species Cat. 
Number 
Isotype Clone Fluorophore 
IRF-5 Abcam Rabbit ab193245 IgG EPR60
94 
Alexa Fluor 
488 
CD163 Abcam Rabbit ab189915 IgG EPR14
643-36 
N/A 
 
3.4.1. IHC image acquisition, quantification and statistics 
 
Images were acquired using the NIS-elements software to capture 5 random images 
on the Nikon Eclipse 90i microscope (Nikon Inc. Minato, Tokyo, Japan) at x20 
magnification with oil immersion. Images were analyzed using a validated ImageJ 
(National Institute of Health, Bethesda, Maryland) algorithm to quantify the percentage 
of DAB staining present in each image as previously described by Franklin and 
colleagues (Franklin et al., 2014). Briefly, the algorithm divides the acquired image in 
a red, green, and blue colour space into separate colour channels by a colour 
deconvolution method. For each antibody stain, DAB threshold levels were manually 
determined and kept constant for each antibody dataset. The percentage of DAB 
staining was quantified as the percentage of the total field area stained positive for 
DAB. Statistical analyses and graphs were done using GraphPad Prisms (GraphPad 
Software, La Jolla, CA, USA). Due to the small number of participants included in the 
study, medians and interquartile ranges were used, and tested for signficance using 
non-parametric testing.  
3.4.2. IF image acquisition 
 
Immunofluorescence images were acquired on a Zeiss LSM880 Airy Scan (Zeiss, 
Oberkochen, Germany) confocal microscope using a 40x Plan-Apochromatic oil 
immersion objective (numerical aperture, 0.95). The fluorophores for DAPI, Alexa 
Fluor 488 and Cy were excited using the 405, 488 and 633-nm laser lines, 
respectively. All channels were acquired sequentially to avoid bleed-through and the 
two-dimensional image was reconstructed using the Zeiss 2.1 software (Zeiss, 
Oberkochen, Germany). Composite images were created using ImageJ (National 
Institute of Health). 
  38 
4. Expression of classical M1 and M2 
macrophage markers on decidual 
macrophages and Hofbauer cells 
 
4.1. Introduction 
 
It is now standard of care for HIV-1 infected women to be on ART once their HIV status 
is known. However, some women are only diagnosed with HIV infection during 
pregnancy and the implications of the timing of ART initiation on adverse birth 
outcomes are not yet fully understood. Uthman and colleagues reported that women 
who initiated ART before conception were significantly more likely to deliver preterm 
and low-birthweight infants than those who initiated ART after conception  (Uthman et 
al., 2017). Another study reported that a tenofovir disoprixil fumarate, emtricitabine, 
and efavirenz (TDF-FTC-EFV) regimen was associated with lower risk for adverse 
birth outcomes than other commonly prescribed ART regimens in women who initiated 
ART before conception (Zash et al., 2017). The impact of HIV-1 and/ ART exposure 
on the phenotype and function of immune cells of the maternal-foetal interface is not 
yet clear. In this chapter, placental samples were investigated for presence of 
macrophages in relation to the timing of ART initiation: before or during gestation. It is 
hypothesized that HIV and/ ART exposure dysregulates the balance of 
immunoregulatory and pro-inflammatory macrophages at the maternal-foetal 
interface. 
 
4.2.  Results  
 
To investigate the effect of the duration of ART exposure on birth outcome and 
placenta pathology, we compared birth outcomes and placenta pathologies of HIV-
infected women categorized into two groups, 1). HIV-1 infected pregnant women who 
initiated ART at during of pregnancy (at +/- 20 weeks of gestation) (Initiating ART 
n=16); and 2). HIV-1 infected women who initiated ART before pregnancy (Stable on 
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ART n=14). Table 4.1 shows a summary of the characteristics of women, their infants 
and placentas from the two study groups. At birth, the median age of women who were 
stable on ART before pregnancy was significantly higher than that of women who 
initiated ART at around 20 weeks of gestation (p=0.01; Mann-Whitney; Fig. 4.1A). 
Overall, there were no significant differences in the birth weight of infants born to 
women who initiated ART before pregnancy compared to those born to women who 
initiated ART during pregnant. There was no statistical significant difference in 
gestational age between these two groups, although, there were more women in the 
initiating group with gestational age of  40 weeks compared to women in the stable 
on ART before pregnancy group (p>0.05; Mann-Whitney; Fig. 4.1C). There were also 
no statistical significant differences in placental basal plate weight, umbilical cord 
length and umbilical cord insertion from the nearest margin of the basal plate between 
these two study groups (p>0.05; Mann-Whitney; Fig. 4.1D, E & F). These data suggest 
that the timing of ART initiation has no effect on these in HIV-1 infected mothers. 
 
Table 4.1: Characteristics of placentas from women who were stable on ART before 
pregnancy (Stable on ART) and women who initiated ART at +/- 20 weeks of gestation 
(Initiating ART). 
 INITIATING ART STABLE ON ART 
Sample Size (n) 16 14 
Mean Age at Delivery 28.6 31.8 
Mean Gestational Age 
(weeks) 
38.3 38.7 
Mean Birth weight (g) 3071 3088 
Mean Umbilical Cord 
length (mm) 
369 311 
Mean Cord Insertion from 
the nearest margin (mm) 
48.5 45.2 
Basal Plate weight (g) 408.1 398.1 
Chorioamnionitis* 3/11 (27%) 1/11 (9%) 
   * Presence or absence of Chorioamnionitis was reported in 11 pathology reports in 
both study groups 
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Figure 4.1: Differences in the characteristics of women, infants and their placentas 
between the two study groups. A comparison of (A) the median age of mothers at 
delivery (B) Infant’s birth weight (C) gestational age in months (D) Placental basal 
plate weight (E) umbilical cord insertion from the nearest margin of the placenta basal 
plate, and (F) the umbilical cord length between the two study groups.  
 
To investigate the effect of the duration of ART exposure on the phenotype of decidual 
macrophages and Hofbauer cells, placental tissue sections, DP, DB and VT were 
stained with Meyer’s hematoxylin & Eosin (H&E), pan-macrophage marker (CD68), 
Scavenger receptor (CD163), Mannose receptor (CD206) and DC-SIGN (CD209). 
CD68 is a 110kD intracellular glycoprotein that is associated with cytoplasmic 
granules. Its expression localizes in the cytoplasm of macrophages and other 
mononuclear phagocytes (Gottfried et al., 2008). CD163 is a scavenger receptor for 
haptoglobin-hemoglobin complex that is highly expressed on the cell membrane of 
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monocytes and macrophages (Buechler et al., 2000). CD206 is a mannose receptor 
that is highly expressed by macrophages, dendritic cells and Langerhans cells 
(Martinez-Pomares, 2012). CD209 is the dendritic cell-specific ICAM-grabbing non-
integrin that is highly expressed by macrophages and dendritic cells (Soilleux, 2003). 
In this study, M2 macrophages were regarded as CD68 positive cells that also express 
CD163, CD206 and CD209 while M1 macrophages are those that only express CD68. 
The staining controls for these markers are shown in Figure 4.2A-D.  
 
 
Figure 4.2: Isotype control, negative control and positive control for each marker. (A) 
CD68 control staining on human tonsil sections (B) CD163 control staining on human 
placental villi tissue (C) CD206 control staining on human lung tissue, and (D) CD209 
control staining on human placental decidual basalis.  
There were conspicuous differences in the staining pattern and specificities of the 
markers on control tissues used (Fig. 4.2), where these differences may be due to 
differences in antigen retrieval method, tissues and antigenicity of each marker. Figure 
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4.4 and Figure 4.5 are representative IHC images of placental membranes from a 
participant initiating ART during pregnancy and stable on ART before pregnancy 
respectively. H&E staining of the placental membranes making up the maternal-foetal 
interface revealed differences in tissue histology between the membranes. The villous 
tissue of participants initiating ART during pregnancy had larger and conspicuous 
intervilli spaces compared to the villous tissue of participants stable on ART before 
pregnancy (Figure 4.3 A& B). We also observed that most villi tissue of participants 
that were stable on ART before pregnancy had more maternal blood contamination 
compared to that of participants that initiated ART during pregnancy (Figure 4.3B). 
The significance of larger or smaller intervilli spaces is not yet known. Histologically, 
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there was no visible differences between the maternal decidual membranes, DP and 
DB within each group and between the two ART groups.  
 
Figure 4.3: Histological differences in the villous tissue between a participant who 
initiated ART during pregnancy (A) and a participant who was stable on ART before 
pregnancy (B).  
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Figure 4.4: Representative IHC images of placental membranes from a participant 
initiating ART during pregnancy. (A) Hematoxylin and Eosin (H&E) staining (B) CD68, 
(C) CD163, (D) CD206, and (E) CD209 staining of the villous tissue, decidua basalis 
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and decidua parietalis of a placenta from a mother who initiated ART during 
pregnancy. 
 
Figure 4.5: Representative IHC images of placental membranes from a participant 
who was stable on ART before pregnancy. (A) Hematoxylin and Eosin (H&E) staining 
(B) CD68, (C) CD163, (D) CD206, and (E) CD209 staining of the villous tissue, 
decidua basalis and decidua parietalis of a placenta from a mother who was stable on 
ART before pregnancy. 
 
CD68+ (Figure 4.4B and Figure 4.5B); CD163+ (Figure 4.4C and Figure 4.5C); 
CD206+ (Figure 4.4D and Figure 4.5D); and CD209+ (Figure 4.4E and Figure 4.5E) 
  46 
macrophages were differentially distributed between the membranes of the maternal-
foetal interface. In all placental tissue sections stained irrespective of when ART was 
initiated (n=30); the number of CD68+ Hofbauer cells (foetal-derived macrophages in 
the villous tissue) was significantly higher than that of decidual macrophages of the 
decidua basalis (p<0.0001; Mann-Whitney; Fig. 4.6A) and decidua parietalis 
(p<0.0001; Mann-Whitney; Fig. 4.6A). The decidual macrophages of the decidua 
basalis had significantly higher CD68 expression than those of the decidua parietalis 
(p=0.0101; Mann-Whitney; Fig. 4.6A). There was no significant difference in CD163 
expression between Hofbauer cells (HCs) and decidual macrophages of the decidua 
basalis (DB), and between decidual macrophages of the decidua basalis and decidua 
parietalis (Fig 4.6B). However, the number of CD163+ HCs was significantly higher 
than that of decidual macrophages of the decidua parietalis (p<0.0001; Mann-Whitney; 
Fig. 4.6B, ns refers to p-values greater than 0.05). Interestingly, there were more 
decidual macrophages of the DB expressing CD163 compared to the Hofbauer cells 
of the villous tissue and the other decidual macrophages of the DP. The expression of 
Mannose receptor (CD206) by HCs was significantly higher than that of the decidual 
macrophages of the DB (p<0.0001; Mann-Whitney; Fig. 4.6C) and DP (p=0.0007; 
Mann-Whitney; Fig. 4.6C).  CD206+ decidual macrophages were higher in the DP 
compared to the DB (p=0.0043; Mann-Whitney; Fig. 4.6C). There was no difference 
in the number of CD209+ decidual macrophages between the DB and DP (Fig. 4.6D). 
The number of CD209+ HCs was significantly higher than both the CD209+ decidual 
macrophages of the DB (p<0.0001; Mann-Whitney; Fig. 4.6D) and DP (p=0.0009; 
Mann-Whitney; Fig. 4.6D). 
 
 
 
 
  47 
 
 
Figure 4.6: Differential distribution of classical M1 and M2 macrophage markers on 
the decidual macrophages and Hofbauer cells of the maternal-foetal interface of 
placentas from HIV-1 infected mothers. Distribution of (A) CD68+ cells, (B) CD163+ 
cells, (C) CD206+ cells and, (D) CD209+ cells in the villous tissue, decidua basalis 
and decidua parietalis of HIV-1 infected mothers. 
 
Comparison of each of these macrophage marker expression in each membrane of 
the maternal-foetal interface between ART study groups was made. CD68 expression 
on Hofbauer cells was slightly higher in the villous tissue of placentas from women 
who initiated ART during pregnancy compared with those who were on ART before 
pregnancy. However, their median values were not statistically significant (Fig. 4.7A).  
There were also no significant differences for all our markers of interest between 
Hofbauer cells and decidual macrophages of women who initiated ART during 
pregnancy compared to those women on ART prior to pregnancy (Fig. 4.7B, C &D).  
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Figure 4.7: Effect of the duration of ART exposure on the distribution of classical M1 
and M2 macrophage markers on decidual macrophages and Hofbauer cells of women 
who initiated ART before pregnancy compared to those whom initiated ART during 
pregnancy. Differences in the distribution of (A) CD68+ cells, (B) CD163+ cells, (C) 
CD206+ cells and, (D) CD209+ cells in the villous tissue (VT), decidua basalis (DB) 
and decidua parietalis (DP). 
 
The activation status of decidual macrophages and Hofbauer cells in the two study 
groups was further investigated by immunofluorescence (IF) staining of placental 
tissues, DP, DB and VT with the M1-specific marker, interferon regulatory factor-5 
(IRF-5) and the M2-specific marker, CD163 (as described above). Figure 4.8. shows 
IF staining controls. IRF-5 is a member of the interferon-regulatory factor (IRF) family 
is involved in the activation of genes encoding type I interferon and pro-inflammatory 
cytokines such as tumor necrosis factor (TNF), IL-6, IL-12 and IL-13 (Krausgruber et 
al., 2011a). It has been identified as a specific marker for inflammatory M1 
macrophages (Krausgruber et al., 2010a, Weiss et al., 2013). As described previously, 
CD163 is a plasma membrane glycoprotein, a member of the scavenger receptor 
cysteine-rich super family class B (Fabriek et al., 2005) and a marker of regulatory M2 
macrophages. The macrophage populations at the maternal-foetal interface (VT, DB 
and DP) of HIV-1 infected women, co-expressed markers associated with M1 (IRF-5) 
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and M2 (CD163) polarisation, irrespective of the time of ART initiation (merged images 
in Fig.4.9A-C, Fig. 4.10A-C and Fig. 4.11).  
 
 
 
Figure 4.8: Immunofluorescence (IF) staining controls. (A) staining of placental villous 
tissue with DAPI and Cy3-labeled donkey anti-rabbit secondary antibody. (B) staining 
of placental villous tissue with DAPI and a non-specific isotype control, Rabbit IgG. 
Showing no non-specific staining of both the secondary antibody and the antibody 
isotype. 
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Figure 4.9: Representative IF images of placental membranes from a participant that 
initiated ART during pregnancy. (A) Villous Tissue staining of DAPI (Blue), IRF-5 
(Green), CD163 (Red) and the composite image (B) Decidua Basalis staining of DAPI 
(Blue), IRF-5 (Green), CD163 (Red) and the composite image (C) Decidua Parietalis 
staining of DAPI (Blue), IRF-5 (Green), CD163 (Red) and the composite image. 
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Figure 4.10: Representative IF images of placental membranes from a participant that 
was stable on ART before pregnancy. (A) Villous Tissue staining of DAPI (Blue), IRF-
5 (Green), CD163 (Red) and the composite image (B) Decidua Basalis staining of 
DAPI (Blue), IRF-5 (Green), CD163 (Red) and the composite image (C) Decidua 
Parietalis staining of DAPI (Blue), IRF-5 (Green), CD163 (Red) and the composite 
image. 
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Figure 4.11: Merged images showing co-expression of CD163 (red) and IRF-5 
(Green) in (A) Villous Tissue, (B) Decidua Basalis, and (C) Decidua Parietalis.  
 
4.3. Discussion 
 
Upon pathological examination of placentas collected from the women at delivery, it 
was noted that 3/11 (27%) placentas from women who initiated ART during pregnancy 
had chorioamnionitis (CA), an acute inflammation of the placental membranes and the 
chorion due to microbial infections such as Escherichia coli and Group B 
Streptococcus (Czikk et al., 2011, Kawamura et al., 2015) compared to 1/11 (9%) 
placentas examined from women who were stable on ART prior to pregnancy. 
Although the pathophysiology of CA is not yet clear, it is believed to be a consequence 
of  disturbed immune homeostasis at the maternal-foetal interface associated with 
Hofbauer cells (Bracci and Buonocore, 2003). The prevalence of common 
complications of pregnancy such as CA, gestational diabetes mellitus (GDM); and pre-
eclampsia among HIV-infected women in South Africa is not yet known. Numerous 
studies have reported the dysregulation of placental macrophages leading to adverse 
birth outcomes in pregnancies complicated by one or more of the above complications 
(Vinnars et al., 2010, Hung et al., 2006, Toti et al., 2011, Joerink et al., 2011, Sisino et 
al., 2013). 
 
Apart from the mother’s age at birth, all other parameters compared between these 
two study groups were statistically not significantly different. When gestational age 
and infant birth weight at delivery was compared between these two ART groups, there 
was a trend towards preterm birth and low infant birth weight (Fig. 4.1B & Fig. 4.1C) 
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among women who initiated ART during pregnancy. These few outliers infer that 
initiating ART during pregnancy may lead to adverse birth outcomes among HIV-
infected women initiating ART during pregnancy. That would be contradictory to the 
findings of Uthman and colleagues who reported that women who initiate ART before 
pregnancy were significantly more likely to deliver preterm and to have low-birth weight 
infants compared to those who initiate ART during pregnancy (Uthman et al., 2017). 
However, it is also important to note that these differences may be due to differences 
in sample size, population demographics and ART regimens. Although not significant, 
umbilical cord insertions to the basal plate of the placenta and umbilical cord lengths 
were either displaced or shorter in placentas from women who were stable on ART 
before pregnancy, compared with those that initiated ART during pregnancy. What 
this might mean is not yet known. However, we propose that the conspicuous 
histological differences in these placentas may have implications for placental 
functions and subsequent birth outcomes. 
 
In their epidemiological study based on HIV-1 infected South African women, Malaba 
et al., reported no association between the timing of ART initiation (before or during 
pregnancy) and adverse birth outcomes (Malaba et al., 2017). We posit that the 
prevalence of adverse birth outcomes among HIV-1 infected women on ART may not 
be a direct consequence HIV-infection and the timing of ART initiation, but rather be 
due to the predisposition of HIV-1 infected pregnant women to common complications 
of pregnancy such as chorioamnionitis, gestational diabetes mellitus, and pre-
eclampsia. We therefore hypothesize that these complications of pregnancy are the 
main drivers of the dysregulation of immune cells at the maternal-foetal interface 
leading to adverse birth outcomes. In order to fully understand the impact of HIV-
infection and the duration of ART exposure on immune mechanisms regulating 
pregnancy, we propose to further investigate the impact of HIV and/ ART exposure 
exclusively of common complications of pregnancy and compare these to healthy 
controls. The major limitations to our current data is the lack of HIV-1 uninfected or 
healthy participants, a small sample size (n) and the lack of screening of participants 
for common complications of pregnancy (such as CA, pre-eclampsia, and gestational 
diabetes mellitus) at enrolment. 
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5. Identification of Novel Markers of Decidual 
Macrophages and Hofbauer Cells 
 
5.1. Introduction 
 
Phenotypic characterization of macrophages at the maternal-foetal interface is 
incomplete. All markers currently used to phenotype decidual macrophages and 
Hofbauer cells lack specificity and the markers used in most studies to investigate 
macrophages at the maternal-foetal interface are general markers for other tissue-
resident myeloid cells. Cell-specific markers will allow for further characterization of 
these cells regardless of their placental tissue localization. The aim of this chapter was 
to identify novel markers that can be used to isolate and further characterize decidual 
macrophages and Hofbauer cells of the human placenta. A novel approach was 
developed on the human transcriptome database in the Human Protein Atlas 
(www.proteinatlas.org) to identify highly expressed protein-encoding genes in the 
human placenta. Based on their localization, we assigned them to different types of 
cells making-up the placental tissue. According to the transcriptome analysis of the 
Human Protein Atlas, 69% (n=13592) of all human proteins (n=19613) are expressed 
in the placenta. There was an elevated expression of 356 of these genes in the 
placenta compared to other types of tissue. The 356 genes were categorized into 3 
groups summarized in Table 5.1. 
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Table 5.1: Genes with elevated expression in the placenta compared to other organs. 
Category Number of 
genes 
Description 
Group enriched 73  5-fold higher mRNA levels in a group of 
2-7 tissues 
Tissue enriched 78  5-fold higher mRNA levels in a particular 
tissue as compared to all other tissues  
Tissue enhanced 205  5-fold higher mRNA levels in a particular 
tissue as compared to average levels in all 
tissues 
Total 356 Total number of elevated genes in 
placenta 
 
 
5.2. Methods 
 
We used immunohistochemically stained placental-tissue sections of the Human 
Protein Atlas (HPA) (https://www.proteinatlas.org) to visualize placental cell 
localization and expression pattern of the 78 genes defined as tissue-enriched in the 
placenta (Appendix A: Table 1). The flowchart below details the procedure used to 
identify novel markers of decidual macrophages and Hofbauer cells in the human 
placenta. This strategy could be applied to the identification of cellular markers in 
various other tissues. 
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Figure 5.1: Strategy used to identify new markers of decidual macrophages and 
Hofbauer cells. 
 
5.3. Results 
 
Among the 78 placental-tissue enriched genes with at least five-fold higher mRNA 
levels, there are 12 genes that had the highest level of expression. The mRNA level 
(mRNA transcript) and placental cell localization (decidual macrophage, Hofbauer cell 
or other) of these genes are shown in Table 5.2. 
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Table 5.2: Placental cell localization and mRNA transcript level of the 12 genes with 
the highest level of expression in the placenta.  
 
Gene Name 
 
Description 
 
Placental cell 
localization 
mRNA 
transcript 
level 
HBG2 hemoglobin subunit gamma 2 other cells 18253.8 
CSH1 chorionic somatomammotropin 
hormone 1 
Other cells 13487 
CSH2 chorionic somatomammotropin 
hormone 2 
other cells 3932.3 
XAGE3 X antigen family member 3 other cells 575.4 
PSG1 pregnancy specific beta-1-
glycoprotein 1 
other cells 362.6 
PSG2 pregnancy specific beta-1-
glycoprotein 2 
other cells 343.4 
ISM2 isthmin 2 Hofbauer cells & 
other cells 
274.5 
CSHL1 chorionic somatomammotropin 
hormone like 1 
Other cells 216.7 
GH2 growth hormone 2 other cells 189.1 
PSG3 pregnancy specific beta-1-
glycoprotein 3 
other cells  188.8 
PSG5 pregnancy specific beta-1-
glycoproetin 5 
other cells 157.6 
PSG9 pregnancy specific beta-1-
glycoprotein 9 
other cells 147 
 
We observed that the majority of genes that are highly-enriched on the human 
placenta localized to other regions of the placenta such as trophoblast cells and 
endothelial cells. Among the 12/78 (15.3%) genes that had the highest level of 
expression in the placenta, none localized or were expressed by decidual 
macrophages. Isthmin 2 (ISM2) was the only protein that localized to Hofbauer cells, 
although, it was also expressed by other cells within the chorionic villi of the placenta 
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but not the decidua (Figure 5.2). ISM2 has two alternatively spliced transcript variants 
that encodes different isoforms. However, very little is known about ISM1 or ISM2 in 
the human placenta, despite having the highest expression of ISM2 compared to other 
human tissues (Figure 5.3). 
 
 
Figure 5.2: The expression of  Isthmin 2 (ISM2) in the chorionic villi (A) of the placenta 
compared to the decidua (B). 
 
 
Figure 5.3: Expression of Isthmin 2 in the placenta compared to other human tissues.  
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Immunohistochemically stained human placental tissue sections revealed that among 
the 78 genes defined as tissue-enriched in the placenta, 8 (10.3%) were uniquely 
expressed by Hofbauer cells, 5 (6.4%) were expressed by decidual macrophages, 3 
(3.8%) were expressed by both decidual macrophages and Hofbauer cells while the 
remaining 62 (79.5%) were expressed by other cells of the placenta such as 
trophoblasts, fibroblasts and endothelial cells (Figure 5.4). 
  
 
Figure 5.4: Placental localization of the 78 genes enriched in the placenta. 
 
Table 5.3: Genes expressed by Hofbauer cells and their predicted function. 
Gene Name Description Predicted Function 
ISM2 Isthmin 2 For cell adhesion and 
angiogenesis 
EGFL6 EGF like domain multiple 6 Regulates cell cycle, 
proliferation, and 
development processes 
PLAC1 Placenta-specific 1 Plays a role in normal 
embryo development 
FCGR2B Fc fragment of IgG receptor IIb Required for the 
maintenance of tolerance 
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HGF Hepatocyte growth factor Involve in epithelial cell 
proliferation, migration 
and morphogenesis 
VGLL1 Vestigial like family member 1 Specific activator of 
mammalian transcription 
factors 
IL1RL1 Interleukin 1 receptor like 1 Activates MAP kinases 
LIN28B Lin-28 homolog B Regulates gene 
expression 
 
Immunohistochemistry stained placental chorionic villi for Lin-28 homolog B (LIN28B) 
and Placenta-specific-1 (PLAC1) showed high expression of these markers on 
Hofbauer cells (Figure 5.5).  IHC stains of the placental decidua, showed high 
expression of insulin-like growth factor-2 (IGF2) and Pappaliysin-2 (PAPPA-2) on 
decidual macrophages (Figure 5.6).  
 
 
Figure 5.5: Expression of Lin-28 homolog encoded by the LIN28 gene and placenta-
specific 1 protein encoded by the PLAC1 gene on Hofbauer cells. 
(https://www.proteinatlas.org) 
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Figure 5.6: Expression of IGF-2 and PAPPA-2 on decidual macrophages of the 
placenta. (https://www.proteinatlas.org) 
 
A few studies which investigated the human placenta transcriptome reported various 
other genes as highly enriched in the human placenta (Saben et al., 2014, Sood et al., 
2006). The Human Protein Atlas database was used to determine the expression 
pattern of the genes reported by these studies, Coagulation Factor XIII A1 (FXIIIA1) 
and Allograft Inflammatory Factor 1 (AIF-1) was highly expressed specific markers for 
Hofbauer cells (Figure 5.7). Tetratricopeptide Repeat Protein 39B (TTC39B) and 
Exoribonuclease 1 (ERI1) were highly expressed and specific for decidual 
macrophages (Figure 5.8). Table 5.4 and Table 5.5 below, details the other genes that 
were highly expressed by decidual macrophages and Hofbauer cells, respectively. 
While Figure 5.9 shows the expression pattern of enriched genes that are expressed 
on both the chorionic villi (Hofbauer cells and other cells) and decidua of the placenta.  
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Figure 5.7: Expression of Coagulation Factor XIII A1 (FXIIIA1) and allograft 
inflammatory factor 1 (AIF-1) on Hofbauer cells. (https://www.proteinatlas.org) 
 
 
Figure 5.8: The expression of Tetratricopeptide Repeat Protein 39B (TTC39B) and 
Exoribonuclease 1 (ERI1) on decidual macrophages of the placenta. 
(https://www.proteinatlas.org) 
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Table 5.4: Genes expressed by decidual macrophages and their predicted function. 
Gene Name Description Predicted Function 
HLA-G Major histocompatibility complex, 
class I, G 
Induces the immune 
tolerance of the foetus 
IGF-2 Insulin-like growth factor 2 Promotes placental 
differentiation and 
function 
SLC13A4 Solute carrier family 13 member 14 Involved in nutrients 
transport 
PAPPA2 Pappalysin 2 Regulates metabolism 
and nutrient transport 
SKP2 S-phase kinase associated protein 2 Promotes vascular 
smooth muscle cell 
proliferation 
 
 
Table 5.5: Genes expressed by both decidual macrophages and Hofbauer cells and 
their predicted functions 
Gene Name Description Predicted Function 
TRIM64B Tripartite motif containing 
protein 64B 
Autophagy receptor 
regulator 
ADAMTS18 ADAM metallopeptidase 
with thrombospondin type 
1 motif 18 
Involved in extracellular 
matrix degradation 
CHAT Choline O-
acetyltransferase 
Plays a role in the 
synthesis of acetylcholine 
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Figure 5.9: Placental-tissue enriched genes that are expressed on both the chorionic 
villi and decidua of the placenta. The expression of (A) CHAT on the Hofbauer cells of 
the chorionic villi and decidua, (B) ADAMTS18 on the Hofbauer cells of the chorionic 
villi and decidua. (https://www.proteinatlas.org) 
 
 
 
5.4. Discussion 
 
In this chapter we determined placental tissue localization of a number of expressed 
genes that have been shown to be highly-enriched in human placental tissues 
compared to other tissue types. The majority of genes that are highly enriched in 
human placentas, as determined by The Human Protein Atlas, localized to 
trophoblasts and endothelial cells of the placenta and fewer expressed genes 
localized to Hofbauer cells. Those that did included LIN28B, which plays a role in the 
regulation of gene expression (Viswanathan et al., 2008), Placenta-specific-1 (PLAC-
1), which is involved in normal placental and embryonic development (Jackman et al., 
2012, Fant et al., 2010), and EGFL6, which is involved in the regulation of the cell 
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cycle, proliferation, and development processes (Noh et al., 2017). The latter protein, 
suggests a role of Hofbauer cells in placental and foetal development. Along with 
expression expression of a potent angiogenesis inducer, Hepatocyte growth factor 
(HGF) which plays a role in epithelial cell proliferation, migration, and morphogenesis 
further supports the involvement of Hofbauer cells in placental and foetal development 
(Kauma et al., 1997).  
 
The genes localizing to the decidual membrane region of the placenta such as insulin-
like growth factor 2 (IGF-2) and pregnancy-associated plasma protein A2 (PAPPA-2) 
are involved in the regulation of metabolism and nutrient transport (Sibley et al., 2004). 
PAPPA-2 is a metalloproteinase from syncytiotrophoblasts, where it cleaves the 
complex formed between insulin-like growth factor (IGF) and insulin-like growth factor 
binding protein (IGFBP). The expression of PAPPA, PAPPA-2 and PLAC-1 in the 
placenta during pregnancy was recently associated with foetal growth restriction 
(FGR) (Sifakis et al., 2018).  Interestingly, Human Leukocyte Antigen G (HLA-G), a 
non-classical MHC class I molecule that is specifically expressed by invading Extra-
Villous trophoblasts (EVT) earlier on during pregnancy (Kovats et al., 1990) was found 
to be highly expressed by decidual cells and not by Hofbauer cells in (Human Protein 
Atlas). Such differential expression of HLA-G suggests a synergy between the 
induction and maintenance of immune tolerance by foetal (trophoblasts) and maternal 
cells (decidual cells). Coagulation Factor XIII (FXIII) is a transglutaminase enzyme that 
circulates in tetrameric form (FXIII-A2B2). It is made-up of two A subunits (FXIII-A) and 
two B subunits (FXIII-B) and catalyzes the cross-linking of fibrin and stabilizes the 
fibrin clot (Muszbek et al., 2011). It has also been shown to have a role in wound 
healing, bone metabolism and pregnancy (Shi and Wang, 2017).  It has also been 
reported to be a marker for alternative activation of macrophages (Torocsik et al., 
2005). We proposed Coagulation Factor XIIIA chain 1 (FXIIIA1) and Insulin-like growth 
factor 2 as potential specific markers for Hofbauer cells and decidual macrophages, 
respectively. However, these markers require further validation.
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6. Discovering Placental Macrophage-specific 
biomarkers of HIV-infection 
 
6.1. Introduction 
 
There is no available data on the interactions of immunological cells of the maternal-
foetal interface and the maternal immune system exposed to HIV and/or antiretroviral 
drugs. Placental macrophages have been reported to play a central role in the 
establishment and maintenance of immune tolerance towards the semi-allogeneic 
foetus throughout gestation (Svensson-Arvelund and Ernerudh, 2015, Svensson-
Arvelund et al., 2015). Hofbauer cells have also been implicated the vertical 
transmission of TORCH (Toxoplasmosis, other infections, Rubella, Cytomegalovirus 
and Herpes Simplex II virus) infections (Quicke et al., 2016, Simoni et al., 2017), while 
a study by Quillay and colleagues reported that decidual macrophages are permissive 
to HIV-1 infection, in vitro (Quillay et al., 2015). Therefore, there is a need to identify 
biomarkers of placental macrophage dysregulation that can be associated with 
adverse birth outcomes observed in pregnancies complicated by maternal HIV-
infection. Identification of these biomarkers would provide a better understanding of 
HIV pathogenesis amongst pregnant women and provide a foundation for the 
development of therapeutic interventions required to improve birth outcomes and 
maternal health. The aim of this chapter was to discover novel decidual macrophage-
specific and Hofbauer cell-specific biomarkers of HIV-1 infection. 
 
 
6.2. Methods  
 
Existing microarray datasets by Cobos et al., deposited on GEO Profiles (Superseries 
GSE55029) was used. In this particular study, polarized macrophages were obtained 
from healthy, HIV-uninfected donors by the stimulation of isolated primary monocytes 
with IFN-γ (250 U/ml) in combination with TNF (12.5 ng/ml), IL-4 (50 ng/ml), IL-10 (50 
ng/ml) for 5 days. Monocyte-derived macrophages (MDM) were also infected for 24 
hours with one of two HIV-1 strains (CCR5- or CXCR4-using HIV-1) or their non-
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replicating counterparts (heat inactivated virus). Macrophages not stimulated with 
cytokines or uninfected with HIV-1 were used as controls. A total of 16 treatment 
conditions were tested in triplicate, for a total of 48 samples analyzed. To verify protein 
expression in placental tissue, we used the Human Protein Atlas database 
(http://www.proteinatlas.org/). The strategy used to discover novel biomarkers of HIV-
1 infection is outlined in Figure 6.1 below. 
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Figure 6.1: Strategy used to discover novel biomarkers of HIV-1 infection. 
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6.3. Results 
 
Macrophages in the placenta were compared to IL-4, IL-10, HIV-infected, and IFN-
/TNF- treated human monocyte-derived macrophages (MDM). For this study, the 
top 100 genes that were highly upregulated in each treatment group were checked for 
constitutive expression in the Human Protein Atlas database. Localization of these 
genes on placental tissue are represented in Appendix A, Tables II-V. To discover 
novel biomarkers of HIV-1 infection, we focused on genes/markers upregulated by 
CCR5-HIV-1 infection of MDM after 24 hours. Markers that were highly upregulated 
by CCR5-HIV-1 infection of MDM after 24 hours but constitutively expressed by 
decidual macrophages and Hofbauer cells were not regarded as potential biomarkers 
of HIV-infection (Fig. 6.2). The markers that were highly upregulated on these MDM 
but not constitutively expressed by decidual macrophages and Hofbauer cells were 
regarded as potential biomarkers of HIV-1 infection in these cells. Markers Identified 
as potential biomarkers of HIV-1 infection on decidual macrophages and Hofbauer 
cells are shown in Figure 6.3. 
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Figure 6.2: IHC images of markers encoded by genes that are highly upregulated by 
24hr CCR5-HIV infection of MDM. These markers do not represent potential 
biomarkers of HIV infection. (A) Expression of Tetratricopeptide repeat domain 39B 
(TTC39B) and Exoribonuclease 1 (ERI) on decidual cells and, (B) Expression of 
Human Coagulation Factor XIIIA1 (FXIIIA1) and Protein phosphatase 1 regulatory 
subunit 18 (PPP1R18) on Hofbauer cells. (https://www.proteinatlas.org) 
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Figure 6.3: IHC images of markers that are highly upregulated by 24hr CCR5-HIV 
infection of MDM but not constitutively expressed by placental macrophages. These 
represent potential biomarkers of Maternal HIV-infection, (A) Opa Interacting Protein 
5 (OIP5) and Matrix Metallopeptidase 9 (MMP9) in decidual cells and (B) TNF--
induced protein 3-interacting protein 1 (TNIP1) and Transmembrane protein 130 
(TMEM130) on Hofbauer cells. (https://www.proteinatlas.org) 
 
 
6.4. Discussion 
 
In this Ph.D., a novel approach was used to discover new markers that are highly 
upregulated by HIV-1 infection on monocyte-derived macrophages (MDMs) and could 
be used as biomarkers of HIV-1 infection in placental macrophages. Upon HIV-
infection of MDMs, there was an upregulation of Tetratricopeptide repeat domain 39B 
(TTC39B) and Exoribonuclease 1 (ERI) which both localized to decidual 
macrophages; and protein phosphate 1 regulatory subunit 18 (PPP1R18) and 
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Coagulation Factor XIII A chain 1 (F13A1) which localized to Hofbauer cells of the 
placenta chorionic villi. Using the Human Protein Atlas database, it was determined 
that these genes are constitutively expressed on decidual macrophages and placental 
Hofbauer cells, and therefore could not be used as potential biomarkers of HIV-1 
infection in these cells. We identified Opa Interacting Protein 5 (OIP5) and matrix 
metalloproteinase 9 (MMP9) as potential biomarkers of HIV-1 infection in Hofbauer 
cells; and TNF--induced protein 3-interacting protein 1 (TNIP1) and Transmembrane 
protein 130 (TMEM130) as potential biomarkers of HIV-1 infection in decidual 
macrophages as these markers were highly upregulated by HIV-1 infection but not 
constitutively expressed by these macrophages. MMP9 is a major matrix 
metalloproteinase produced by macrophages, but its regulation is not yet known 
(Brown et al., 1995). It cleaves basement membrane collagens type IV and V and 
gelatin, elastin and fibronectin (Vu et al., 1998). The significance of these markers on 
pregnancy is not yet known. As an extension to this work, freshly-isolated placental 
macrophages from HIV-1 exposed and unexposed placentas will be stained to 
determine the expression of these markers. We will also determine the 
permissiveness of placenta-isolated decidual macrophages and Hofbauer cells to HIV-
1 infection, in vitro. Due to the ambiguity in the ontogeny of these cells, it is not known 
whether monocyte-derived macrophages are a good model for decidual macrophages 
or Hofbauer cells. 
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7. Conclusions and Limitations 
 
The work presented in this thesis focused on understanding the effect of maternal HIV 
infection and the duration of ARV drug exposure on the expression of markers 
associated with M1 and M2 polarisation of macrophages by placental macrophages, 
decidual macrophages and foetal Hofbauer cells. The immunohistochemistry data 
presented in this thesis showed histological differences between placental 
membranes (VT, DB and DP) making-up the maternal-foetal interface. Although 
similar to one another, the maternal-derived placental membranes, the decidua 
basalis and decidua parietalis, are different in cellular composition and architecture 
from the foetal-derived, chorionic villous tissue (VT). 
 
Due to lack of M1 macrophage-specific markers, in this study, M1 macrophages 
(classically activated) were defined as cells expressing the pan-macrophage marker, 
CD68 while lacking the expression of M2 macrophage-associated markers, CD163, 
CD206 and CD209. The data presented in this thesis showed that the expression of 
CD68 is higher on Hofbauer cells compared to decidual macrophages (DB and DP) in 
placentas from HIV-1 infected mothers. The expression of CD206 and CD209, but not 
CD163, was also higher on Hofbauer cells compared to decidual macrophages. These 
data suggest that decidual macrophages and Hofbauer cells in HIV-1 infected women 
are not polarized in accordance with the M1/M2 paradigm of macrophage polarization, 
but rather express markers associated with both inflammation (M1) and immune 
regulation (M2). This is supported by the immunofluorescence imaging data which 
showed the co-expression of IRF-5, a transcription factor associated with classical 
(M1) activation; and CD163, a marker associated with alternative (M2) activation, on 
both Hofbauer cells and decidual macrophages of placentas from HIV-1 infected 
mothers. There were no significant differences in the expression of these markers by 
Hofbauer cells, decidual macrophages of the DB and decidual macrophages of the 
DP in placentas from HIV-1 infected women who initiated ART before pregnancy and 
those who initiated ART during pregnancy. Based on these results, we conclude that 
the duration of ART exposure has no effect on the expression of macrophage markers 
associated with classical and alternative activation of Hofbauer cells and decidual 
macrophages from HIV-1 infected mothers. However, a major limitation to these data 
  74 
is the lack of immunofluorescence images quantification tool. Therefore, these 
conclusions are only based on qualitative assessment of the IF images.  
 
Immunohistochemistry (IHC) is a routine diagnostic and basic research technique, 
however, it does have limitations. The number of steps involved in IHC such as tissue 
preparation and fixation, paraffin block preparation, antigen retrieval methods, 
reagents and antibody specificities, incubation, washing steps and counterstaining 
may introduce a variety of confounders. There are other techniques available with the 
same principle as IHC, such as the EnVision system (DAKO, Hamburg, Germany). 
The EnVision system is a highly sensitive two-step immunohistochemical technique 
that takes less time to prepare than regular IHC (Kammerer et al., 2001). Apart from 
advances in experimental protocols which can now allow for the visualization of 
several antigens in a single multiplexed IHC experiment, imaging technology has also 
advanced tremendously. In recent years, a number of high resolution microscopes 
have been developed. However, a tissue-specific method to quantify antigen 
expression is a major limitation, especially in resource-limited settings. 
 
We identified Coagulation Factor XIIIA1 (FXIIIA1) and Insulin-like growth factor 2 (IGF-
2) as potential constitutive markers for Hofbauer cells and decidual macrophages 
respectively. Using a microarray dataset of Cobos et al., and the Human Protein Atlas 
database, we also identified OIP5 and MMP9 as potential biomarkers of HIV-1 
infection in Hofbauer cells, and TNIP1 and TMEM130 as potential biomarkers of HIV-
1 infection in decidual macrophages. Although the strategy of identifying new markers 
for tissue-resident cells is yet to be validated, this approach was used to identify novel 
markers for placental macrophage populations. A further limitation in this Ph.D. was 
to validate this strategy using placenta-isolated macrophages from placentas collected 
in the cohort study using multicolor flow cytometry, IHC and immunofluorescence 
staining. One potential limitation of using MDM is that these cells do not represent HC 
in the placenta and may have a different transcriptomic profile. However, this was 
outside the scope of this PhD and may need to be addressed in future studies.  To 
further investigate the effect of HIV and or ART exposure on immune mechanisms 
associated with macrophages of the maternal-foetal interface, this work will be 
extended to compare differences in expression of these novel macrophage markers 
with those in HIV-unexposed, healthy pregnancies.  
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9. Appendices  
 
9.1. Appendix A: Gene localization to the human placental 
cells 
 
Table 1: The localization of the 78 placental tissue enriched genes (with at least five-
fold higher mRNA levels) on the Human Protein Database. 
Gene Name Description Placental cell localization 
ADAM12 ADAM metallopeptidase 
domain 12 
Other cells 
ADAMTS18 ADAM metallopeptidase 
with thrombospondin type 
1 motif 18 
Hofbauer Cells & 
Decidual macrophages 
C4orf26 Chromosome 4 open 
reading frame 26 
Other cells 
CGA Glycoprotein hormones, 
alpha polypeptide 
Other cells 
CGB3 Chorionic gonadotropin 
beta subunit 3 
Other cells 
CGB5 Chorionic gonadotropin 
beta subunit 5 
Other cells 
CGB8 Chorionic gonadotropin 
beta subunit 8 
Other cells 
CHAT Choline O-
acetyltransferase 
Hofbauer cells & decidual 
macrophages 
CLEC1A C-type lectin domain 
family 1 member A 
Other cells 
COL11A1 Collagen type XI alpha 1 
chain 
Other cells 
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CSH1 Chorionic 
somatomammotropin 
hormone 1 
Other cells 
CSH2 Chorionic 
somatomammotropin 
hormone 2 
Other cells 
CSHL1 Chorionic 
somatomammotropin 
hormone like 1 
Other cells 
CYP19A1 Cytochrome P450 family 
19 subfamily A member 1 
Other cells 
EBI3 Epstein-Barr virus 
induced 3 
Other cells 
EGFL6 EGF like domain 
multiple6 
Hofbauer cells 
EPYC Epiphycan Other cells 
ERVV-1 Endogenous retrovirus 
group V member 1 
Other cells 
ERVV-2 Endogenous retrovirus 
group V member 2 
Other cells 
ERVW-1 Endogenous retrovirus 
group W member 1 
Other cells 
FAM26D Family with sequence 
similarity 26 member 
Other cells 
FBN2 Fibrillin 2 Other cells 
FCGR2B Fc fragment of IgG 
receptor IIb 
Other cells 
FLT1 Fms related tyrosine 
kinase 1 
Other cells 
FOXI3 Fork head box I3 Other cells 
GCM1 Glial cells missing 
homolog 1 
Other cells 
GH2 Growth Hormone 2 Other cells 
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GNGT1 G protein subunit gamma 
transducing 1 
Other cells 
GPC3 Glycan Other cells 
HAPLN1 Hyaluronic and 
proteoglycan link protein 
1 
Other cells 
HBG1 Hemoglobin subunit 
gamma 1 
Other cells 
HBG2 Hemoglobin subunit 
gamma 2 
Other cells 
HGF Hepatocyte growth factor Hofbauer cells 
HLA-G Major histocompatibility 
complex, class I, G 
Decidual macrophages 
HSD17B1 Hydroxylated 17-beta 
dehydrogenase 1 
Other cells 
HSD3B1 Hydroxy-delta-5-steriod 
dehydrogenase, 3 beta-
and steroid delta-
isomerase 1 
Other cells 
HTRA4 HTRA serine peptidase 4 Other cells 
IGF2 Insulin-like growth factor 2 Decidual macrophages 
IL1RL1 Interleukin 1 receptor like 
1 
Hofbauer cells 
INSL4 Insulin like 4 Other cells 
ISM2 Isthmin 2 Hofbauer cells 
KISS1 Kiss-1 metastasis-
suppressor 
Other cells 
KRTAP26-1 Keratin associated protein 
26-1 
Other cells 
LGALS13 Galectin 13 Other cells 
LGALS14 Galectin 14 Other cells 
LGALS16 Galectin 16 Other cells 
LIN28B Lin-28 homolog B Hofbauer cells 
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MAGEA8 MAGE family member A8 Other cells 
MEST Mesoderm specific 
transcript 
Other cells 
MSMP Macroseminoprotein, 
prostate associated 
Other cells 
NFE4 Nuclear factor, erythroid 4 Other cells 
NOTUM NOTUM, palmitoyl-protein 
carboxylesterase 
Other cells 
PAPPA Pappalysin 1 Other cells 
PAPPA2 Pappalysin 2 Decidual macrophages 
PHLDA2 Pleckstrin homology like 
domain family A member 
2 
Other cells 
PLAC1 Placenta specific 1 Hofbauer cells 
PLAGL1 PLAG1 like zinc finger 1 Other cells 
PRG2 Proteoglycan 2, pro 
eosinophil major basic 
protein 
Other cells 
PSG1 Pregnancy specific beta-
1-gycoprotein 1 
Other cells 
PSG11 Pregnancy specific beta-
1-glycoprotein 11 
Other cells 
PSG2 Pregnancy specific beta-
1-glycoprotein 2 
Other cells 
PSG3 Pregnancy specific beta-
1-glycoprotein 3 
Other cells 
PSG5 Pregnancy specific beta-
1-glycoprotein 5 
Other cells 
PSG6 Pregnancy specific beta-
1-glycoprotein 6 
Other cells 
PSG8 Pregnancy specific beta-
1-glycoprotein 8 
Other cells 
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PSG9 Pregnancy specific beta-
1-glycoprotein 9 
Other cells 
SERPINE2 Serpin family E member 2 Other cells 
SIGLEC6 Sialic acid binding Ig like 
lectin 6 
Other cells 
SKP2 S-phase kinase 
associated protein 2 
Decidual macrophages 
SLC13A4 Solute carrier family 13 
member 4 
Decidual macrophages 
TAC3 Tachykinin 3 Other cells 
TFPI2 Tissue factor pathway 
inhibitor 2 
Other cells 
TRIM64 Tripartite motif containing 
64 
Other cells 
TRIM64B Tripartite motif containing 
64B 
Hofbauer cells & decidual 
macrophages 
VGLL1 Vestigial like family 
member 1 
Hofbauer cells 
WNT3A Wnt family member 3A Other cells 
XAGE2 X antigen family 2 Other cells 
XAGE3 X antigen family 3 Other cells 
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Table II: Placenta localization of proteins encoded by genes highly regulated by HIV-
1 infection of MDM. 
Gene Symbol Gene Name Placental cell localization 
ABCA1 ATP binding cassette 
subfamily A member 1 
Decidual macrophages 
ABHD6 abhydrolase domain 
containing 6 
Decidual macrophages 
ADAMDEC1 ADAM like decysin 1 Other cells 
ADORA2A adenosine A2a receptor Other cells 
AKR1B1 aldo-keto reductase 
family 1 member B 
Other cells 
AMPD3 adenosine 
monophosphate 
deaminase 3 
Other cells  
ASF1B anti-silencing function 1B 
histone chaperone 
Other cells 
BCAT1 branched chain amino 
acid transaminase 1 
Other cells  
BOK BOK, BCL2 family 
apoptosis regulator 
Other cells 
C15orf48 chromosome 15 open 
reading frame 48 
Other cells 
C15orf48 chromosome 15 open 
reading frame 48 
Other cells 
CACNB4 calcium voltage-gated 
channel auxiliary subunit 
beta 4 
Other cells 
CCDC85C coiled-coil domain 
containing 85C 
Decidual macrophages 
CCND1 cyclin D1 Other cells 
CDC20 cell division cycle 20 Hofbauer cells 
CDK1 cyclin dependent kinase 1 Decidual macrophages 
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CENPM centromere protein M Other cells 
CEP55 centrosomal protein 55 Other cells 
CHCHD7 coiled-coil-helix-coiled-
coil-helix domain 
containing 7 
Other cells 
COQ2 coenzyme Q2, 
polyprenyltransferase 
Other cells 
CTNNAL1 catenin alpha like 1 Other cells 
CTSD cathepsin D Other cells 
CXCL8 C-X-C motif chemokine 
ligand 8 
Other cells 
CXCL8 C-X-C motif chemokine 
ligand 8 
Other cells 
DACT1 dishevelled binding 
antagonist of beta catenin 
1 
Other cells 
DLGAP5 DLG associated protein 5 Other cells 
DLGAP5 DLG associated protein 5 Other cells 
DNASE1L3 Deoxy-ribonuclease 1 like 
3 
Both Hofbauer cells & 
decidual macrophages 
DRAM1 DNA damage regulated 
autophagy modulator 1 
Other cells  
EBI3 Epstein-Barr virus 
induced 3 
Other cells 
ECHDC3 enoyl-CoA hydratase 
domain containing 3 
Other cells 
EHD1 EH domain containing 1 Other cells 
EMP1 epithelial membrane 
protein 1 
Other cells 
ERI1 exoribonuclease 1 Decidual macrophages 
F13A1 coagulation factor XIII A 
chain 
Hofbauer cells 
FCHO1 FCH domain only 1 Other cells 
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FN1 fibronectin 1 Hofbauer cells 
GK glycerol kinase Other cells 
GPSM2 G-protein signaling 
modulator 2 
Other cells 
GRAMD1A GRAM domain containing 
1A 
Other cells 
HADHB hydroxyacyl-CoA 
dehydrogenase/3-
ketoacyl-CoA 
thiolase/enoyl-CoA 
hydratase (trifunctional 
protein), beta subunit 
Other cells 
HINT3 histidine triad nucleotide 
binding protein 3 
Decidual macrophages 
HMMR hyaluronan mediated 
motility receptor 
Other cells 
IER3 immediate early response 
3 
Other cells 
INSIG1 insulin induced gene 1 Other cells 
IRAK2 interleukin 1 receptor 
associated kinase 2 
Decidual macrophages 
IRF1 interferon regulatory 
factor 1 
Other cells 
ITGAV integrin subunit alpha V Other cells 
KIAA0101 KIAA0101 Other cells 
KIF20B kinesin family member 
20B 
Decidual macrophages 
KLF4 Kruppel-like factor 4 Hofbauer cells 
MAP1S microtubule associated 
protein 1S 
Other cells 
MELK maternal embryonic 
leucine zipper kinase 
Other cells 
MMP9 matrix metallopeptidase 9 Other cells 
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MTF1 metal regulatory 
transcription factor 1 
Other cells 
NFKB2 nuclear factor kappa B 
subunit 2 
Other cells 
OGFRL1 opioid growth factor 
receptor like 1 
Other cells 
OIP5 Opa interacting protein 5 Other cells 
OSBPL1A oxysterol binding protein 
like 1A 
Other cells 
PCM1 pericentriolar material 1 Other cells 
PCSK5 Pro-protein convertase 
subtilisin/kexin type 5 
Other cells 
PDPN podoplanin Other cells 
PNKD paroxysmal 
nonkinesigenic dyskinesia 
Other cells 
POLQ DNA polymerase theta Other cells 
PPP1R14A protein phosphatase 1 
regulatory inhibitor 
subunit 14A 
Hofbauer cells 
PPP1R18 protein phosphatase 1 
regulatory subunit 18 
Hofbauer cells 
PRC1 protein regulator of 
cytokinesis 1 
Other cells 
PTGFRN prostaglandin F2 receptor 
inhibitor 
Other cells 
RAB3IL1 RAB3A interacting protein 
like 1 
Other cells 
RAMP1 receptor activity modifying 
protein 1 
Other cells 
RBM11 RNA binding motif protein 
11 
Other cells 
RRP1B ribosomal RNA 
processing 1B 
Both Hofbauer cells & 
decidual macrophages 
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SASH3 SAM and SH3 domain 
containing 3 
Other cells 
SIGLEC8 sialic acid binding Ig like 
lectin 8 
Other cells 
SLC22A15 solute carrier family 22 
member 15 
Other cells 
SLC2A6 solute carrier family 2 
member 6 
Other cells 
SLC43A3 solute carrier family 43 
member 3 
Decidual macrophages 
SNTB1 syntrophic beta 1 Decidual macrophages 
SOD2 superoxide dismutase 2, 
mitochondrial 
Other cells 
STARD10 StAR related lipid transfer 
domain containing 10 
Other cells 
TMEM130 transmembrane protein 
130 
Other cells 
TNFAIP3 TNF alpha induced 
protein 3 
Decidual macrophages 
TNFSF15 tumor necrosis factor 
superfamily member 15 
Decidual macrophages 
TNFSF9 tumor necrosis factor 
superfamily member 9 
Other cells 
TNIK TRAF2 and NCK 
interacting kinase 
Other cells 
TNIP1 TNFAIP3 interacting 
protein 1 
Other cells 
TOP2A topoisomerase (DNA) II 
alpha 
Other cells 
TPX2 TPX2, microtubule 
nucleation factor 
Other cells 
TRAF5 TNF receptor associated 
factor 5 
Other cells 
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TREM2 triggering receptor 
expressed on myeloid 
cells 2 
Other cells 
TTC39B tetratricopeptide repeat 
domain 39B 
Decidual macrophages 
UBE2C ubiquitin conjugating 
enzyme E2 C 
Decidual macrophages 
UHRF1 ubiquitin like with PHD 
and ring finger domains 1 
Other cells 
WFS1 wolframin ER 
transmembrane 
glycoprotein 
Other cells 
ZC3H12A zinc finger CCCH-type 
containing 12A 
Other cells 
ZDHHC19 zinc finger DHHC-type 
containing 19 
Other cells 
ZSWIM4 zinc finger SWIM-type 
containing 4 
Other cells 
 
 
Table III: Placenta localization of proteins encoded by genes highly regulated by IL-4 
on MDM. 
Gene Symbol Gene Name Placental cell 
localization 
ACAA2 acetyl-CoA 
acyltransferase 2 
Other cells 
ACTN1 actinin, alpha 1 Other cells 
ADSL adenylosuccinate lyase Other cells 
AIF1 allograft inflammatory 
factor 1 
Hofbauer cells 
ALDH1A2 aldehyde dehydrogenase 
1 family, member A2 
Other cells 
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ALOX5AP Arachidonate 5-
lipoxygenase-activation 
protein 
Both Hofbauer cells & 
decidual macrophages 
ANXA4 annexin A4 Other cells 
APOC2 Apopoliprotein C-II Other cells 
APOE apopoliprotein E Other cells 
AQP9 Aquaporin 9 Other cells 
ATP5C1 ATP synthase, H+ 
transporting, mitochondrial 
F1 complex, gamma 
polypeptide 1 
Other cells 
BCAR3 Breast cancer anti-
estrogen resistance 3 
Other cells 
CBR1 carbonyl reductase 1 Other cells 
CD14 CD14 Molecule Both Hofbauer cells & 
decidual macrophages 
CD37 CD37  molecule Other cells 
CFL1 cofilin 1 (non-muscle) Hofbauer cells 
CH25H Cholesterol 25-
hydroxylase 
Other cells 
CISH Cytokine inducible SH2-
containing protein 
Other cells 
CLTA clathrin, light chain A Both Hofbauer cells & 
decidual macrophages 
COTL1 coactosin-like 1 
(Dictyostelium) 
Hofbauer cells 
COX6B1 cytochrome c oxidase 
subunit Vib polypeptide 1 
Other cells 
CSTB cystatin B (stefin B) Other cells 
CTSA cathepsin Decidual macrophages 
CTSD cathepsin D Other cells 
CTSS cathepsin S Other cells 
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CXCL2 Chemokine (C-X-C motif) 
ligand 2 
Other cells 
CYBB cytochrome b-245, beta 
polypeptide  
Hofbauer cells 
CYFIP1 cytoplasmic FMR1 
interacting protein 1 
Other cells 
DBI diazepam binding inhibitor 
(GABA receptor 
modulator) 
Other cells 
DDOST dolichyl-
diphosphooligosaccharide-
proetin glycosltransferase 
Other cells 
DPYSL2 dihydropyrimidinase-like 2 Hofbauer cells 
DUSP6 Dual specificity 
phosphatase 6 
Other cells 
EIF4E eukaryotic translation 
initiation factor 4E 
Other cells 
EIF5A eukaryotic translation 
initiation factor 5A 
Decidual macrophages 
ESD esterase D Other cells 
ESYT1 extended synaptotagmin-
like proetin 1 
Other cells 
GARS glycyl-tRNA sythetase Other cells 
GLB1 galactosidase, beta 1 Other cells 
GLS glutaminase Other cells 
GRB2 growth factor-bound 
protein 2 
Hofbauer cells 
GRN granulin Decidual macrophages 
GSR glutathione reductase Other cells 
GUSB glucurinidase, beta Other cells 
HIST1H1C histone cluster 1, H1c Both Hofbauer cells & 
decidual macrophages 
HK3 hexokinase 3 (white cell) Hofbauer cells 
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HMOX2 heme oxygenase 
(decycling) 2 
Decidual macrophages 
HSPA9 heast shock 70kDa proetin 
(mortalin) 
Decidual macrophages 
IFITM3 Interferon induced 
transmembrane proetin 3 
Other cells 
IRF4 Interferon regulatory factor 
4 
Other cells 
ITGAM integrin, alpha M 
(complement comonent 3 
receptor 3 subunit) 
Decidual macrophages 
KLF4 Kruppel-like factor 4 (gut) Both Hofbauer cells & 
decidual macrophages 
KLHL6 Kelch-like 6 Other cells 
KRT1 keratin 1 Other cells 
LPAR6 Lysophosphatidic acid 
receptor 
Other cells 
LRPAP1 low density lipoproetin 
receptor-related proetin 
associated proetin 1 
Decidual macrophages 
MRC1 Mannose receptor, C type 
1 
Both Hofbauer cells & 
decidual macrophages 
MYC v-myc myelocytomatosis 
viral oncogene homolog 
Other cells 
NAGA N-
acetylgalactosominidase, 
alpha 
Hofbauer cells 
NCL nucleolin Both Hofbauer cells & 
decidual macrophages 
NDUFA4 NADH dehydrogenase 
(ubiquinone) 1 alpha 
subcomplex, 4, 9kDa 
Other cells 
NUCB1 nucleobinding 1 Other cells 
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OTUB1 OUT domain, ubiquitin 
aldehyde binding 1 
Other cells 
PDCD1LG2 Programmed cell death 1 
ligand 2 
Other cells 
PLD3 phospholipase D family, 
member 3 
Other cells 
PPIA peptidylprolyl isomerase A 
(cyclophilin A) 
Other cells 
PPT1 palmitoyl-protein 
thioesterase 1 
Other cells 
PRDX1 peroxiredoxin 1 Hofbauer cells 
PRDX3 peroxiredoxin 3 Other cells 
PSMD2 proteosome 26S subunit, 
non-ATPase, 2 
Other cells 
PTGS1 Prostaglandin-
endoperoxidase synthase 
1 
Other cells 
PTK2B PTK2B protein tyrosine 2 
beta 
Other cells 
PTPRC protein tyrosine 
phosphatase, receptor 
type C 
Other cells 
PYCARD PYD and CARD domain 
containing 
Hofbauer cells 
RGL1 Ral guanin nucleotide 
dissociation stimulator-like 
1 
Other cells 
RPL4 ribosomal protein L4 Other cells 
RPS10 ribosomal protein S10 Other cells 
RPS15 ribosomal protein S15 Decidual macrophages 
RPS23 ribosomal protein S23 Other cells 
S100A11 S100 calcium binding 
protein A11 
Other cells 
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S100A8 S100 calcium binding 
protein A8 
Other cells 
SEPHS2 Selenophosphate 
synthetase 2 
Other cells 
SEPP1 selenoprotein P, plasma 1 Hofbauer cells 
SERPINB6 serpin peptide inhibitor, 
clade B, member 6 
Other cells 
SHMT2 Serine 
hydroxymethlytransferase 
2 
Decidual macrophages 
SLA Src-like-adapter Other cells 
SLC9A9 Solute carrier family 9, 
member 9 
Other cells 
SNX2 sorting nexin 2 Both Hofbauer cells & 
decidual macrophages 
SOCS1 Suppressor of cytokine 
signaling 1 
Other cells 
SORL1 Sortilin-related receptor, 
L(DLR class) A repeats 
containing 
Other cells 
SPARC secreted protein, acidic, 
cysteine-rich 
Other cells 
TAPBP TAP binding protein 
(tapasin) 
Other cells 
TBCB tubulin folding cofactor B Other cells 
TFRC transferrin receptor (p90, 
CD71) 
Decidual macrophages 
TGM2 Transglutaminase 2 Other cells 
TXNRD1 thioredixin reductase 1 Other cells 
UBA1 ubiquitin-like modifier 
activating enzyme 1 
Decidual macrophages 
UBE2V1 ubiquitin-conjugating 
enzyme E2 variant 1 
Other cells 
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VPS35 vacuolar protein sorting 35 
homolog (S. cerevisiae) 
Other cells 
 
 
Table IV: Placenta localization of proteins encoded by genes highly-regulated by IL-
10 stimulation on MDM. 
Gene Symbol Gene Name Placental cell localization 
ACADVL Acyl-CoA dehydrogenase, 
very long chain 
Other cells 
ACAT1 Acetyl-CoA 
acetyltransferase 1 
Both Hofbauer cells & 
decidual macrophages 
ACTL6A Actin like 6A Other cells 
ADORA2A Adenosine A2a receptor Other cells 
AKR1B1 Aldo-keto reductase 
family 1 member B 
Other cells 
APOPT1 Apoptogenic 1, 
mitochondrial 
Other cells 
ATG4C Autophagy related 4C 
cysteine peptidase 
Other cells 
C12orf57 chromosome 12 open 
reading frame 57 
Other cells 
C16orf59 Chromosome 16 open 
reading frame 59 
Other cells 
C1S Complement component 
1, s subcomponent 
Other cells 
C3orf38 Chromosome 3 open 
reading frame 38 
Other cells 
CBWD5 COBW domain containing 
5 
Hofbauer cells 
CD274 CD274 molecule Other cells 
CDK1 Cyclin dependent kinase 
1 
Decidual macrophages 
CENPM Centromere protein M Other cells 
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CHCHD7 Coiled-coil-helix-coiled-
coil-helix domain 
containing 7 
Other cells 
CHD8 Chromodomain helicase 
DNA binding protein 8 
Other cells 
CHMP3 Charged multi-vesicular 
body protein 3 
Other cells 
CNIH1 Cornichon family AMPA 
receptor auxiliary protein 
1 
Other cells 
COQ2 coenzyme Q2, 
polyprenyltransferase 
Other cells 
COX20 COX20, cytochrome c 
oxidase assembly factor 
Other cells 
DLGAP5 DLG associated protein 5 Other cells 
DNASE2B Deoxyribonuclease 2 beta Other cells 
DYNC1H1 dynein cytoplasmic 1 
heavy chain 1 
Other cells 
ECI2 Enoyl-CoA delta 
isomerase 2 
Other cells 
ERAP2 Endoplasmic-reticulum 
aminopeptidase 2 
Decidual macrophages 
ESD Esterase D Other cells 
ETNK1 Ethanolamine kinase 1 Other cells 
FBXO8 F-box protein 8 Other cells 
FGD5 FYVE, RhoGEF and PH 
domain containing 5 
Other cells 
FOXO3 Fork head box O3 Other cells 
GNB4 G protein subunit beta 4 Other cells 
GPSM2 G-protein signaling 
modulator 2 
Other cells 
GTSE1 G2 and S-phase 
expressed 1 
Other cells 
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H2AFZ H2A histone family 
member Z 
Both Hofbauer cells & 
decidual macrophages 
HADH Hydroxyacyl-CoA 
dehydrogenase 
Hofbauer cells 
HINT3 Histidine triad nucleotide 
binding protein 3 
Decidual macrophages 
HMGB2 High mobility group box 2 Other cells 
HMGN1 High mobility group 
nucleosome binding 
domain 1 
Both Hofbauer cells & 
decidual macrophages 
HMMR Hyaluronic mediated 
motility receptor 
Other cells 
IRF1 Interferon regulatory 
factor 1 
Other cells 
ITGAV Integrin subunit alpha V Decidual macrophages 
KIAA0101 KIAA0101 Other cells 
KIF15 Kinesin family member 15 Other cells 
KIF20B kinesin family member 
20B 
Hofbauer cells 
KPNA6 Karyopherin subunit alpha 
6 
Other cells 
LBR Lamin B receptor Both Hofbauer cells & 
decidual macrophages 
LOC101926963 Uncharacterized 
LOC101926963 
Other cells 
LRRFIP1 LRR binding FLII 
interacting protein 1 
Other cells 
LSS Lanosterol synthase (2,3-
oxidosqualene-lanosterol 
cyclase) 
Other cells 
LYPLAL1 Lysophospholipase like 1 Decidual macrophages 
MAD2L1 MAD2 mitotic arrest 
deficient-like 1 (yeast) 
Other cells 
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MAP3K7 Mitogen-activated protein 
kinase kinase kinase 7 
Other cells 
MAPK3 Mitogen-activated protein 
kinase 3 
Both Hofbauer cells & 
decidual macrophages 
MAT2B Methionine 
adenosyltransferase 2B 
Other cells 
MAX MYC associated factor X Decidual macrophages 
MDFIC MyoD family inhibitor 
domain containing 
Other cells 
MMP12 Matrix metallopeptidase 
12 
Other cells 
MMP14 Matrix metallopeptidase 
14 
Hofbauer cells 
MORC3 MORC family CW-type 
zinc finger 3 
Hofbauer cells 
MRPL18 mitochondrial ribosomal 
protein L18 
Decidual macrophages 
MTMR11 Myotubularin related 
protein 11 
Decidual macrophages 
NUSAP1 Nucleolar and spindle 
associated protein 1 
Other cells 
OIP5 Opa interacting protein 5 Other cells 
OIP5 Opa interacting protein 5 Other cells 
OPLAH 5-oxoprolinase (ATP-
hydrolysing) 
Other cells 
PGK1 phosphoglycerate kinase 
1 
Other cells 
PLXDC2 Plexin domain containing 
2 
Other cells 
POLQ DNA polymerase theta Other cells 
PPA1 Pyrophosphatase 
(inorganic) 1 
Other cells 
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PPIAL4A peptidylprolyl isomerase 
A like 4A 
Other cells 
PRDX3 Peroxiredoxin 3 Hofbauer cells 
RAD51AP1 RAD51 associated protein 
1 
Other cells 
RFC4 Replication factor C 
subunit 4 
Both Hofbauer cells & 
decidual macrophages 
ROCK2 Rho associated coiled-coil 
containing protein kinase 
2 
Other cells 
RRM1 Ribonucleotide reductase 
catalytic subunit M1 
Other cells 
SEMA3E Semaphorin 3E Decidual macrophages 
SH3BGR SH3 domain binding 
glutamate rich protein 
Other cells 
SLC44A1 Solute carrier family 44 
member 1 
Other cells 
SRP9 signal recognition particle 
9 
Other cells 
STARD10 StAR related lipid transfer 
domain containing 10 
Other cells 
STMN1 Stathmin 1 Hofbauer cells 
TAGLN3 Transgelin 3 Other cells 
TCEAL8 Transcription elongation 
factor A like 8 
Other cells 
TNFSF15 Tumor necrosis factor 
superfamily member 15 
Decidual macrophages 
TNFSF9 Tumor necrosis factor 
superfamily member 9 
Other cells 
TOP2A Topoisomerase (DNA) II 
alpha 
Other cells 
TP53BP2 Tumor protein p53 
binding protein 2 
Decidual macrophages 
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TPX2 TPX2, microtubule 
nucleation factor 
Decidual macrophages 
TRIM16L Tripartite motif containing 
16-like 
Other cells 
TROVE2 TROVE domain family 
member 2 
Other cells 
TYW3 tRNA-yW synthesizing 
protein 3 homolog 
Other cells 
UBE2C Ubiquitin conjugating 
enzyme E2 C 
Decidual macrophages 
XPNPEP3 X-prolyl aminopeptidase 3 Other cells 
ZC3H12A Zinc finger CCCH-type 
containing 12A 
Other cells 
ZFAND6 Zinc finger AN1-type 
containing 6 
Other cells 
ZMAT3 Zinc finger matrin-type 3 Other cells 
ZNF394 Zinc finger protein 394 Other cells 
ZWINT ZW10 interacting 
kinetochore protein 
Other cells 
 
 
Table V: Hofbauer Cell and decidual macrophage localization of 100 proteins encoded 
by genes highly regulated by TNF- (12.5 ng/ml) and IFN- (250 U/ml) on MDM.  
 
Gene Symbol Gene Name Placental cell localization 
ACADVL acyl-CoA dehydrogenase, 
very long chain 
Other cells 
ANLN anillin actin binding 
protein 
Other cells 
APBA3 amyloid beta precursor 
protein binding family A 
member 3 
Other cells 
APOBR apolipoprotein B receptor Other cells 
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ARAP3 ArfGAP with RhoGAP 
domain, ankyrin repeat 
and PH domain 3 
Other cells 
ARRB1 arrestin beta 1 Other cells 
ASF1B anti-silencing function 1B 
histone chaperone 
Other cells 
ASPM abnormal spindle 
microtubule assembly 
Other cells 
ATP2A3 ATPase 
sarcoplasmic/endoplasmic 
reticulum Ca2+ 
transporting 3 
Other cells 
AURKB aurora kinase B Other cells 
BIRC5 baculoviral IAP repeat 
containing 5 
Other cells 
BUB1 BUB1 mitotic checkpoint 
serine/threonine kinase 
Other cells 
C12orf57 chromosome 12 open 
reading frame 57 
Other cells 
C16orf59 chromosome 16 open 
reading frame 59 
Other cells 
CAMSAP2 calmodulin regulated 
spectrin associated 
protein family member 2 
Decidual macrophages 
CARHSP1 calcium regulated heat 
stable protein 1 
Other cells 
CASC3 cancer susceptibility 
candidate 3 
Other cells 
CCDC14 coiled-coil domain 
containing 14 
Other cells 
CCM2 CCM2 scaffolding protein Decidual macrophages 
CCNA2 cyclin A2 Other cells 
CCNB1 cyclin B1 Other cells 
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CCNB2 cyclin B2 Other cells 
CCNF cyclin F Other cells 
CD6 CD6 molecule Other cells 
CDC20 cell division cycle 20 Other cells 
CDCA3 cell division cycle 
associated 3 
Other cells 
CDCA5 cell division cycle 
associated 5 
Other cells 
CDK1 cyclin dependent kinase 1 Decidual macrophages 
CENPE centromere protein E Other cells 
CENPM centromere protein M Other cells 
CENPU centromere protein U Other cells 
CEP55 centrosomal protein 55 Other cells 
CKAP2L cytoskeleton associated 
protein 2 like 
Hofbauer cell 
CKS2 CDC28 protein kinase 
regulatory subunit 2 
Other cells 
CLIC2 chloride intracellular 
channel 2 
Other cells 
DLGAP5 DLG associated protein 5 Other cells 
E2F2 E2F transcription factor 2 Other cells 
FDFT1 farnesyl-diphosphate 
farnesyltransferase 1 
Other cells 
FGD5 FYVE, RhoGEF and PH 
domain containing 5 
Other cells 
GTSE1 G2 and S-phase 
expressed 1 
Other cells 
H2AFZ H2A histone family 
member Z 
Hofbauer cells & decidual 
macrophages 
HELLS helicase, lymphoid-
specific 
Other cells 
HIST1H4C histone cluster 1, H4c Other cells 
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HJURP Holliday junction 
recognition protein 
Other cells 
HMGB2 high mobility group box 2 Other cells 
HMMR hyaluronan mediated 
motility receptor 
Other cells 
HVCN1 hydrogen voltage gated 
channel 1 
Other cells 
INSIG1 insulin induced gene 1 Other cells 
IRF1 interferon regulatory factor 
1 
Other cells 
KIAA0101 KIAA0101 Other cells 
KIF11 kinesin family member 11 Other cells 
KIF14 kinesin family member 14 Decidual macrophages 
KIF15 kinesin family member 15 Other cells 
KIF20A kinesin family member 
20A 
Hofbauer cells 
KIF20B kinesin family member 
20B 
Hofbauer cells 
KIF23 kinesin family member 23 Other cells 
LDHB lactate dehydrogenase B Other cells 
LOC101926963 uncharacterized 
LOC101926963 
Other cells 
LSM10 LSM10, U7 small nuclear 
RNA associated 
Other cells 
MAD2L1 MAD2 mitotic arrest 
deficient-like 1 (yeast) 
Other cells 
MCM10 minichromosome 
maintenance 10 
replication initiation factor 
Other cells 
MELK maternal embryonic 
leucine zipper kinase 
Other cells 
MTMR10 myotubularin related 
protein 10 
Other cells 
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NCAPG non-SMC condensin I 
complex subunit G 
Decidual macrophages 
NDC80 NDC80, kinetochore 
complex component 
Other cells 
NUSAP1 nucleolar and spindle 
associated protein 1 
Other cells 
OIP5 Opa interacting protein 5 Other cells 
OPLAH 5-oxoprolinase (ATP-
hydrolysing) 
Other cells 
PARPBP PARP1 binding protein Other cells 
PLK4 polo like kinase 4 Other cells 
PLXDC2 plexin domain containing 
2 
Other cells 
POLQ DNA polymerase theta Other cells 
POLQ DNA polymerase theta Other cells 
PRC1 protein regulator of 
cytokinesis 1 
Other cells 
PRKCDBP protein kinase C delta 
binding protein 
Other cells 
RFC4 replication factor C 
subunit 4 
Other cells 
RILP Rab interacting lysosomal 
protein 
Other cells 
SASH1 SAM and SH3 domain 
containing 1 
Hofbauer cells & decidual 
macrophages 
SKP2 S-phase kinase-
associated protein 2, E3 
ubiquitin protein ligase 
 
Decidual macrophages 
SLC18B1 solute carrier family 18 
member B1 
Other cells 
STIL SCL/TAL1 interrupting 
locus 
Other cells 
STMN1 stathmin 1 Hofbauer cells 
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SUZ12 SUZ12 polycomb 
repressive complex 2 
subunit 
Other cells 
TK1 thymidine kinase 1 Other cells 
TOP2A topoisomerase (DNA) II 
alpha 
Other cells 
TPX2 TPX2, microtubule 
nucleation factor 
Other cells 
TROAP trophinin associated 
protein 
Other cells 
TTK TTK protein kinase Other cells 
TYMS thymidylate synthetase  
UBE2C ubiquitin conjugating 
enzyme E2 C 
Decidual macrophages 
ZNF385A zinc finger protein 385A Other cells 
ZNF428 zinc finger protein 428 Other cells 
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9.2. Appendix B: Protocol for leukocyte isolation from the 
maternal-foetal interface 
1. For decidua parietalis macrophage-isolation, dissect a piece of the 
chorioamniotic membrane. Remove amnion and carefully scrape the DP 
from the chorion using fine-point forceps. Place DP tissue into a 50ml falcon 
tube. 
2. For decidua basalis macrophage-isolation, dissect chorionic villi from the 
basal plate of the placenta and carefully scrape off the villi from the foetal 
side. Place the remaining DB tissue into a 50ml falcon tube. 
3. For Hofbauer cell isolation, dissect the chorionic villi of the placenta, free of 
contamination by the decidua basalis and place into a 50ml falcon tube.  
4. Fill the falcon tubes containing decidual tissue and chorionic villi with 1x 
PBS to remove blood clots, and mince the tissues into small pieces using 
scissors.  
5. When the supernatant is clear, fill the tubes with RPMI medium containing 
1x penicillin-streptomycin (P/S) and wash once (1000 rpm for 1 minute).  
6. Remove the supernatant and digest the remaining placental tissue in 1% 
collagenase IV + 0.1% DNase I in RPMI medium (10 ml per 5ml of tissue) 
and incubate for 75 minutes at 37oC in a shaking water bath. 
7. Prepare the following Percoll solutions, 70% in RPMI 1640 medium with 
1xP/S, 45% in 1xPBS, 50% in RPMI 1640 medium with 1xP/S). Prepare 
the Percoll gradients in a 50ml tube (1 gradient per 5ml of original sample) 
as follows: 
a) 10 ml of 70% Percoll solution 
b) Carefully pipette 15 ml of the 45% Percoll solution on top to form 2 
phases. Keep in 4oC until sample is ready. 
8. After digestion, fill up the sample tubes with RPMI containing 10% FCS and 
1x P/S and wash once (1800 rpm, 7 min). 
9. Remove the supernatant and re-suspend the remaining pellet in 15-20 ml 
of serum free RPMI medium containing 1x P/S and 0.1% DNase I. 
10.  Filter the sample first in the metallic strainer to the big petri plate and then 
collect the filtrate and filter in 3 successive filters - 100µm pore, 70µm pore 
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and 40 µm pore into 50ml Falcon tubes. Use a bulb pipette to stir the tissue 
in the filter, and add media during the process to help the filtration. 
11. Fill up the last collection tube with serum free RPMI medium containing 1x 
P/S and wash once (1800rpm, 7 min). 
12. After washing, remove the supernatant and re-suspend the sample in 10 
ml of serum free RPMI medium containing 1x P/S (per 5ml of original 
sample), and add 10ml of 50% Percoll solution (per 5ml of original sample), 
to obtain a 25% solution. 
13. Carefully pipette 20ml of the mixture of sample, media and 50% Percoll 
solution on top of the 45% Percoll phase per tube. 
14. Carefully pipette 5ml of PBS on top of the sample phase. 
15. Centrifuge at 2000 rpm, 25 min without acceleration and deceleration. After 
spinning, the tube will look like Figure 3.2.1. 
16. Remove the top layer with the junk, and use bulb pipettes to collect the cell 
rings to 50ml Falcon tubes. Use more tubes per sample if collecting a lot of 
Percoll. Fill the tubes with serum free RPMI medium containing 1x P/S and 
wash once (7 min, 2000 rpm). 
17. Combine the tubes from the same samples into one, refill with RPMI 
medium containing 1x P/S and wash again (7 min, 1800 rpm). 
18. Placenta-isolated cells are now ready for subsequent experiments. 
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9.3. Appendix C: Protocol for tissue processing using 
Leica TP 1020 Processor 
 
Formalin-fixed placental tissues were trimmed and placed onto labeled-cassettes for 
processing. Each sample had to go through the following reactions on the processor: 
 
1. 10% formalin - Fixative 
2. 10% formalin – 2 hours 
3. 70% ethanol – 2 hours 
4. 96% ethanol – 2 hours 
5. 96% ethanol – 2 hours 
6. 100% ethanol – 2 hours 
7. 100% ethanol – 2 hours 
8. 100% ethanol – 2 hours 
9. 100% ethanol – 2 hours 
10. Xylene – 2 hours 
11. Xylene – 2 hours 
12. Wax (55-60oC) with vacuum – 2 hours 
13. Wax (55-60oC) with vacuum – 2 hours 
14. Samples are now ready for embedding on the Leica EG1140H. 
 
9.3.1. Mayer’s Hematoxylin and Eosin (H&E) staining 
Protocol 
 
Preparing Mayer’s Hematoxylin stock solution: 
1. Add 1g of Mayer’s Hematoxylin (Sigma-Aldrich, St. Louis, MO, USA) into 1 Liter 
of distilled water and allow to dissolve by stirring gently.  
2. Add 50g of Potassium Sulphate (Sigma-Aldrich, St. Louis, MO, USA). 
3. Add 0.2g of Sodium Iodate (Sigma-Aldrich, St. Louis, MO, USA). 
4. Add 1g Citric acid (Sigma-Aldrich, St. Louis, MO, USA) and allow the solvents 
to dissolve by stirring gently. 
5. Add 50g Chloral hydrate (Saarchem Merck Chemicals, Gauteng, SA). 
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6. Mix well and allow solution to cool. Filter and store in the dark at room 
temperature. 
Preparing Eosin Y stock solution: 
 
1. Add 1% Eosin Y aqueous (Sigma-Aldrich, St. Louis, MO, USA) and 1g Eosin Y 
dye (Sigma-Aldrich, St. Louis, MO, USA) into 100ml distilled water. 
2. Add 1% of Phloxine B (Sigma-Aldrich, St. Louis, MO, USA). 
3. Mix well and store in the dark at room temperature. 
Staining Method: 
1. Dip slides into 3x Xylene and 3x absolute alcohol solutions for 1 minutes in 
each. 
2. Dip slides into 96% ethanol for 2 minutes and then 70% ethanol for 2 minutes. 
3. Rinse slides using tap water. 
4. Dip slides into Mayer’s Hematoxylin solution for 9 minutes. 
5. Rinse slides using tap water. 
6. Dip slides into Scott’s water (Sigma-Aldrich, St. Louis, MO, USA) for 3 minutes. 
7. Dip slides into 1% Eosin solution for 3 minutes. 
8. Rinse slides using tap water. 
9. Dip slides into 70% and 100% ethanol for 3 minutes respectively. 
10. Mount slides using Entellan and store in the dark at room temperature until 
image acquisition. 
 
9.3.2. Immunohistochemistry staining protocol 
 
1. Place formalin-fixed paraffin-embedded slides in an incubator at 560C for at 
least 2 hours. 
2. Dip slides into 3x Xylene and 3x absolute alcohol solutions for 1 minutes in 
each. 
3. Antigen retrieval, for CD68 (Abcam 49777 mouse monoclonal antibody) and 
CD209 (Abcam 5715 rabbit polyclonal) staining, incubate slides in a pre-heated 
pressure cooker containing 10mM Tris/EDTA buffer (pH9) for 2 minutes. For 
CD163 (Abcam 189915 rabbit monoclonal) and CD206 (Abcam 1176441 
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mouse monoclonal) staining, incubate slides in a pre-heated pressure cooker 
containing 10nM Citrate buffer (pH6) for 2 minutes. 
4. Cool slides to room temperature using tap water. 
5. Wash slides using PBST. 
6. For CD68 and CD163, incubate slides with primary antibodies at 1:100 and 
1:500 dilutions respectively for 90 minutes at room temperature. For CD206: 
incubate slides with CD206 primary antibody at 1:100 dilutions overnight at 4oC. 
For CD209: incubate slides with CD209 primary antibody at 1:100 dilutions for 
90 minutes at room temperature.  
7. Wash slides using PBST. 
8. For CD68 and CD206, incubate slides with Dako anti-mouse Envision (Dako 
K4001) for 30 minutes at room temperature. For CD163 and CD209, incubate 
slides with Dako anti-Rabbit Envision (Dako K4003) for 30 minutes at room 
temperature. 
9. Wash slides using PBST. 
10. Detect by staining with the DAB Substrate (Dako K3468) for 10 minutes. 
11.  Wash slides using tap water. 
12.  Counterstain slides with Mayer’s Hematoxylin for 4 minutes.  
13. Wash slides with tap water. 
14. Dip slides into 3x clean tap water and 3x xylene solution for 1 minutes in each. 
15.  Coverslip using Entallan, seal and keep in the dark at room temperature until 
image acquisition.  
 
9.3.3.  Immunofluorescence staining protocol 
 
1. Place formalin-fixed paraffin-embedded slides in an incubator at 560C for at 
least 2 hours. 
2. Dip slides in 3x Xylene and 3x absolute alcohol solutions for 1 minute in each. 
3. For antigen retrieval, place slides in a pre-heated pressure-cooker containing 
10nM Citrate buffer (pH6) and allow pressure to build-up for 2 minutes. 
4. Cool slides to room temperature using tap water. 
5. Block non-specific binding of antibodies using 5% normal goat serum and 
incubate in a moist chamber for 60 minutes. 
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6. Wash slides with PBST. 
7. Dry the slides and mark the location of your tissue using the hydrophobic Novo 
Pen (Leica Biosystems, Wetzler, Germany). 
8. Incubate slides with primary antibodies in the dark at room temperature for 90 
minutes. 
9. Wash slides 3x with PBST. 
10. Incubated slides with secondary antibodies in the dark at room temperature for 
30 minutes. 
11. Wash slides with PBST. 
12. For intracellular staining, Permeabilize cells on the tissue section using 0.1% 
Triton X100. For 10 minutes. 
13.  Wash slides 3x with PBST. 
14. Incubate slides with the second primary antibody and incubate in the dark at 
4oC overnight. 
15. The following day, wash the slide with PBST. if the second primary antibody is 
not conjugated to a fluorophore. Detect accordingly using an appropriate 
secondary antibody for 30 minutes. 
16.  Wash the slides using PBST. 
17. Stain with DAPI and incubate at room temperature for 20 minutes. 
18. Wash the slides using PBST. 
19. To quench tissue autofluorescence, incubate slides with 0.1% Sudan Black B 
in 70% ethanol in the dark for 10 minutes. 
20. Wash slides using PBST. 
21. Mount slides using fluorescence mounting medium. 
22. Seal slides and store at 4oC until acquisition. 
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9.4. Appendix D: Original Review Manuscript 
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